Optimized antibodies targeting TROP2 and uses thereof
Optimizing the TROP2 binding domain and the binding CD3 domain through alanine scanning mutagenesis, solving the problem of insufficient TROP2 binding accumulation and cytotoxic activity in the prior art, and achieving the reduction of accumulation and enhancement of tumor cell killing efficacy in healthy tissues Effect.
Patent Information
- Application Number
- CN202380035018.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-17
- Filing Date
- 2023-02-22
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to reduce the accumulation of tumor-associated calcium signal transducer protein 2 (TROP2) binding in healthy tissues, while maintaining the binding capacity and activity of TROP2, and the recombinant antibody or antigen-binding fragments have insufficient killing activity in tumor cells in vitro.
Optimize the TROP2 binding domain through alanine scanning mutagenesis, and systematically mutate individual residues into alanine to establish CDR3-related structural activity relationships, optimize the dissociation rate and cytotoxic activity of recombinant antibodies or antigen-binding fragments. and bind to the CD3 binding domain to enhance the targeted activity of T cells.
It achieved the reduction of TROP2 binding accumulation in healthy tissues while maintaining TROP2 binding ability and activity, and significantly improved the killing efficacy against tumor cells and enhanced the cytotoxic activity against TROP2.
Smart Images

Figure CN119072497A_ABST
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 313,167, filed on February 23, 2022, and U.S. Provisional Application No. 63,485,687, filed on February 17, 2023, the entire contents of each of which are incorporated herein by reference.
[0003] Sequence Listing
[0004] This application contains a sequence listing submitted electronically in XML format, the entire contents of which are hereby incorporated by reference. The XML copy was created on February 6, 2023, named 52426-740_601SL.xml and is 208,000 bytes in size. Summary of the invention
[0005] Disclosed herein is a recombinant antibody or antigen-binding fragment comprising a tumor-associated calcium signal transducer protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprises complementary determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 1; wherein CDR2-L comprises the amino acid sequence of SEQ ID NO: 2. NO:2 amino acid sequence; and wherein CDR3-L comprises the amino acid sequence of X1X2HYX3X4X5X6X7; wherein X1 is Q, S, T, D, N, E, H, R, K or A; X2 is Q, S, T, D, N, E, H, K, R or A; X3 is I, G, P, V, L, M, S, T or A; X4 is T, G, S, M, H, N, Q or A; X5 is P, G, V, L, I, M, S, T or A; X6 is L, G, P, V, I, M, S, T or A; and X7 is T, G, S, M, H, N, Q or A; wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:13; wherein CDR2-H comprises the amino acid sequence of SEQ ID NO:14; and wherein CDR3-H comprises AX8X9GX 10 X 11 X 12 X 13 YW 14 X 15 X 16 X 17 wherein X8 is R, S, T, Q, D, E, N, H, K or A; X9 is G, P, V, L, I, M, S, T or A; X 10is F, Y, W, V, L, I, G, or A; X 11 is G, P, V, L, I, M, S, T, or A; X 12 is S, G, T, M, N, Q, H or A; X 13 is S, G, T, M, N, Q, H or A; X 14 is Y, F, W, V, L, I, G, or A; X 15 is F, Y, W, V, L, I, G, or A; X 16 is D, Q, N, E, S, T, H, K, R, or A; and X 17 is V, G, P, L, I, M, S, T or A; and wherein when CDR3-H comprises the amino acid sequence of SEQ ID NO: 15, CDR3-L does not comprise the amino acid sequence of SEQ ID NO: 3. In some embodiments, X1 is Q, N, D, E or A; X2 is Q, N, D, E or A; X3 is I, V, L or A; X4 is T, S or A; X5 is P, G or A; X6 is L, V, I or A; X7 is T, S or A; X8 is R, K or A; X9 is G, S, T or A; X 10 is F, Y or A; X 11 is G, S, T or A; X 12 is S, G, T or A; X 13 is S, G, T or A; X 14 is Y, W, F or A; X 15 is F, Y, W or A; X 16 is D, E, Q, N, or A; and X 17 is V, L, I or A. In some embodiments, X1 is Q; and X6 is L. In some embodiments, X8 is R; X 10 It is F;X 11 It is G; X 14 It is Y; X 15 is F; and X 16 It is D.
[0006] In some embodiments, X1 is Q, S, T, D, N, E, or A; X2 is Q, S, T, D, N, E, or A; X3 is I, G, P, V, L, M, or A; X4 is T, G, S, M, H, N, Q, or A; X5 is P, G, V, L, I, M, or A; X6 is L, G, P, V, I, M, or A; X7 is T, G, S, M, H, N, Q, or A; X8 is R, H, K, or A; X9 is G, P, V, L, I, M, S, T, or A; X 10 is F, Y, W, V, L, I or A; X 11 is G, P, V, L, I, M, S, T, or A; X 12 is S, G, T, M, N, Q or A; X13 is S, G, T, M, N, Q or A; X 14 is Y, F, W, V, L, I or A; X 15 is F, Y, W, V, L, I or A; X 16 is D, Q, N, E, S, T, or A; and X 17 is V, G, P, L, I, M or A. In some embodiments, X1 is Q, N or A; X2 is Q, N or A; X3 is I, V, L or A; X4 is T, S or A; X5 is P, G or A; X6 is L, V, I or A; X7 is T, S or A; X8 is R, K or A; X9 is G, V, S, T or A; X 10 is F, Y or A; X 11 is G, V, S, T or A; X 12 is S, G, T or A; X 13 is S, G, T or A; X 14 is Y, W or A; X 15 is F, Y or A; X 16 is D, E, or A; and X 17 is V, G, L, I or A. In some embodiments, X1 is Q; and X6 is L. In some embodiments, X8 is R; X 10 It is F;X 11 It is G; X 14 It is Y; X 15 is F; and X 16 It is D.
[0007] In some embodiments, CDR3-L comprises an amino acid selected from SEQ ID NOs: 3-5, 8-12. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 8 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15. NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:10 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:11 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; and CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 12 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15.In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 8 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 9 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15. NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:10 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:12 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15.
[0008] In some embodiments, CDR3-H comprises an amino acid selected from SEQ ID NOs: 16-17, 19-22, 25-28. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14; CDR3-H: SEQ ID NO: 16; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17. NO:19; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:20; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:22; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 25;CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:26; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:27; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:28. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 21; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 21. NO:22; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:28. ;
[0009] Disclosed herein is a recombinant antibody or antigen-binding fragment comprising a tumor-associated calcium signaling protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the following: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5, and CDR1-H: SEQ ID NO: 6; ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:6 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:7 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:8 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 10 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15;CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:11, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:12, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:16; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:17; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:18; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:19; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:20; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2; CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2;CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14; CDR3-H: SEQ ID NO:22; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:23; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:24; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:25; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:26; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:27; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:28.;
[0010] In some embodiments, the TROP2 binding domain includes Fab, Fab', (Fab')2 or a single-chain variable fragment (scFv). In some embodiments, the TROP2 binding domain is Fab. In some embodiments, the immunoglobulin light chain comprises the variable domain of an immunoglobulin kappa (IgK) or immunoglobulin lambda (IgL) light chain. In some embodiments, the immunoglobulin heavy chain comprises the variable domain of an IgG1, IgG2, IgG3 or IgG4 heavy chain. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to any one of SEQ ID NO:31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71 or 73. In some embodiments, the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NO:32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, or 74. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:31, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:32. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 33, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 34. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 35, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 36.In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 37, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 38. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 42. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 43, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 44. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 45, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 46. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 47, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 48. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:49, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:50.In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 51, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 52. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 53, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 54. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 55, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 56. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 57, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 59, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 60. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 61, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 62. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:63, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:64.In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 65, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 66. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 67, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 68. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 69, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 70. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 71, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 72. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:73, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:74.
[0011] In some embodiments, the TROP2 binding domain has weaker binding to TROP2 than a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO: 29 and an immunoglobulin heavy chain according to SEQ ID NO: 30, as measured by ELISA under substantially similar assay conditions. In some embodiments, the TROP2 binding domain has an increased EC for TROP2 as compared to a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO: 29 and an immunoglobulin heavy chain according to SEQ ID NO: 30, as measured by ELISA under substantially similar assay conditions. 50In some embodiments, the TROP2 binding domain has a faster dissociation rate (greater k) for TROP2 binding as compared to a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO: 29 and an immunoglobulin heavy chain according to SEQ ID NO: 30, as measured under substantially similar kinetic assay conditions. diss ).
[0012] In some embodiments, the recombinant antibody or antigen-binding fragment further comprises a CD3 binding domain. In some embodiments, the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementary determining regions (CDRs) CDR1-L, CDR2-L, and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H, and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 75; wherein CDR2-L comprises the amino acid sequence of SEQ ID NO: 76; wherein CDR3-L comprises the amino acid sequence of SEQ ID NO: 77; wherein CDR1-H comprises the amino acid sequence of SEQ ID NO: 78; wherein CDR2-H comprises the amino acid sequence of SEQ ID NO: 79; and wherein CDR3-H comprises the amino acid sequence of SEQ ID NO: 80.
[0013] In some embodiments, the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementary determining regions (CDRs) CDR1-L, CDR2-L, and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H, and CDR3-H; wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 75; wherein CDR2-L comprises the amino acid sequence of SEQ ID NO: NO:76 amino acid sequence; wherein CDR3-L comprises the amino acid sequence of Z1-Z2-W-Z3-Z4-Z5-Z6-W-Z7-Z8; wherein Z1 is V, G, P, L, I, M, S, T or A; Z2 is L, G, P, V, I, M, S, T or A; Z3 is Y, F, W, V, L, I, G or A; Z4 is S, G, T, M, N, Q, H or A; Z5 is N, Q, S, T, D, E, H, K, R or A; Z6 is R, S, T, Q, D, E, H, K, N or A; Z7 is V, G, P, L, I, M, S, T or A; and Z8 is F, Y, W, V, L, I, G or A; wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:78; wherein CDR2-H comprises SEQ ID NO:79 amino acid sequence; wherein CDR3-H comprises Z9-Z 10 -Z 11 -Z12 -NZ 13 -Z 14 -Z 15 -Z 16 -Z 17 -Z 18 -Z 19 -YZ 20 -AZ 21 wherein Z9 is V, G, P, L, I, M, S, T or A; 10 is R, S, T, Q, D, E, H, K, N, or A; Z 11 is H, R, K, G, T, S, N, Q or A; Z 12 is G, P, V, L, I, M, S, T, or A; Z 13 is F, Y, W, V, L, I, G or A; Z 14 is G, P, V, L, I, M, S, T, or A; Z 15 is N, Q, S, T, D, E, H, K, R or A; Z 16 is S, G, T, M, N, Q, H or A; Z 17 is Y, F, W, V, L, I, G or A; Z 18 is I, G, P, V, L, M, S, T, or A; Z 19 is S, G, T, M, N, Q, H or A; Z 20 is W, F, Y, V, L, I, G, or A; and Z 21 is Y, F, W, V, L, I, G, or A. In some embodiments, Z1 is V, G, L, I, or A; Z2 is L, V, I, or A; Z3 is Y, W, F, or A; Z4 is S, G, T, or A; Z5 is N, Q, D, E, or A; Z6 is R, K, or A; Z7 is V, G, L, I, or A; Z8 is F, Y, W, or A; Z9 is V, G, L, I, or A; Z 10 is R, K or A; Z 12 is G, S, T or A; Z 13 is F, Y, W or A; Z 14 is G, S, T or A; Z 15 is N, Q, D, E or A; Z 16 is S, G, T or A; Z 17 is Y, W, F or A; Z 18 is I, V, L or A; Z 19 is S, G, T or A; Z 20 is W, Y, F or A; and Z 21 is Y, W, F or A. In some embodiments, Z8 is F. In some embodiments, Z 10 It is R; Z 11 It is H; Z13 It is F; Z 18 It is I; Z 19 is S; and Z 20 It's W.
[0014] In some embodiments, CDR3-L comprises an amino acid sequence selected from SEQ ID NOs: 77, 105-106, 108-111, and 113-114. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 105 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 106 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 108 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80. NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80;and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:114 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 105 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 106 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 108 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80. NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80;and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80.;
[0015] In some embodiments, CDR3-H comprises an amino acid sequence selected from SEQ ID NOs: 80, 116-119, 121-127, and 129-130. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 116; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 117; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 117. NO:79, CDR3-H: SEQ ID NO:118; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:121; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:125; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:126; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:127; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:129; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:130. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 116;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ IDNO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ IDNO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:125; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ IDNO:79, CDR3-H: SEQ ID NO:130.;
[0016] In some embodiments, the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L, and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H, and CDR3-H, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 105, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 106, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 80. ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:107 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:108 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:112, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:114, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:116; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:117; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:118; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:120;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:121; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ IDNO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ IDNO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQID NO:125; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:126; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ IDNO:79, CDR3-H: SEQ ID NO:127; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:128;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:129; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:130. ;
[0017] In some embodiments, the immunoglobulin light chain of the CD3 binding domain comprises the variable domain of an immunoglobulin kappa (IgK) or immunoglobulin lambda (IgL) light chain. In some embodiments, the immunoglobulin heavy chain of the CD3 binding domain comprises the variable domain of an IgG1, IgG2, IgG3 or IgG4 heavy chain. In some embodiments, the immunoglobulin light chain of the CD3 binding domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 81. In some embodiments, the immunoglobulin heavy chain of the CD3 binding domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 82. In some embodiments, the immunoglobulin light chain of the CD3 binding domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 81, and the immunoglobulin heavy chain of the CD3 binding domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 82. In some embodiments, the CD3 binding domain comprises a Fab, Fab', (Fab')2 or a single chain variable fragment (scFv). In some embodiments, the CD3 binding domain is a scFv. In some embodiments, the CD3 binding domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 99.
[0018] In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 131. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 132. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 133. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 136. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 137. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 138. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 139. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 140. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 141. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 142. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:143.In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 144. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 145. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 146. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 147. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 148. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 149. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 150. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 151. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 152. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 153. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 154. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 155.
[0019] In some embodiments, the N-terminus of the immunoglobulin heavy chain of the TROP2 binding domain binds to the C-terminus of the immunoglobulin light chain of the CD3 binding domain. In some embodiments, the C-terminus of the immunoglobulin heavy chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin light chain of the CD3 binding domain. In some embodiments, the N-terminus of the immunoglobulin heavy chain of the TROP2 binding domain binds to the C-terminus of the immunoglobulin heavy chain of the CD3 binding domain. In some embodiments, the C-terminus of the immunoglobulin heavy chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin heavy chain of the CD3 binding domain. In some embodiments, the N-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the C-terminus of the immunoglobulin light chain of the CD3 binding domain. In some embodiments, the C-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin light chain of the CD3 binding domain. In some embodiments, the C-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin light chain of the CD3 binding domain. In some embodiments, the N-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the C-terminus of the immunoglobulin heavy chain of the CD3 binding domain. In some embodiments, the C-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin heavy chain of the CD3 binding domain. In some embodiments, the CD3 binding domain is a scFv and the TROP2 binding domain is a Fab or Fab'. In some embodiments, the scFv binds to the immunoglobulin heavy chain of Fab or Fab'. In some embodiments, the scFv binds to the immunoglobulin light chain of Fab or Fab'. In some embodiments, the immunoglobulin light chain of the scFv binds to the immunoglobulin heavy chain of Fab or Fab'. In some embodiments, the immunoglobulin light chain of the scFv binds to the immunoglobulin light chain of Fab or Fab'. In some embodiments, the immunoglobulin heavy chain of the scFv binds to the immunoglobulin heavy chain of Fab or Fab'. In some embodiments, the immunoglobulin light chain of the scFv binds to the immunoglobulin light chain of Fab or Fab'. In some embodiments, the immunoglobulin heavy chain of the scFv binds to the immunoglobulin heavy chain of Fab or Fab'. In some embodiments, the immunoglobulin heavy chain of the scFv is associated with the immunoglobulin light chain of the Fab or Fab'.
[0020] In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 87 and SEQ ID NO: 88. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 89 and SEQ ID NO: 90. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 91 and SEQ ID NO: 92. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 93 and SEQ ID NO: 94. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 95 and SEQ ID NO: 96. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97 and SEQ ID NO: 98.
[0021] In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 188. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 189. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 190. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 194. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 195. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 196.
[0022] In some embodiments, the recombinant antibody or antigen-binding fragment thereof has weaker cytotoxic activity than a recombinant antibody or antigen-binding fragment thereof comprising an immunoglobulin light chain according to SEQ ID NO: 83 or 85 and an immunoglobulin heavy chain according to SEQ ID NO: 84 or 86, as measured in an in vitro tumor cell killing assay under substantially similar assay conditions.
[0023] Disclosed herein is a pharmaceutical composition comprising: (i) the recombinant antibody or antigen-binding fragment thereof according to any one of the embodiments; and (ii) a pharmaceutically acceptable excipient.
[0024] Disclosed herein is an isolated recombinant nucleic acid molecule encoding a polypeptide of the recombinant antibody or antigen-binding fragment thereof according to any one of the above embodiments.
[0025] Disclosed herein is a method for treating cancer in a subject in need thereof, comprising administering to the subject a recombinant antibody or antigen binding fragment thereof of any one of the embodiments. In some embodiments, the cancer comprises breast cancer, lung cancer, urothelial cancer, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, head and neck cancer, or glioma. In some embodiments, breast cancer comprises triple-negative breast cancer. In some embodiments, lung cancer comprises non-small cell lung cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] The novel features of the present disclosure are particularly set forth in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by referring to the following detailed description and accompanying drawings which set forth illustrative embodiments utilizing the principles of the present disclosure, in which:
[0027] Figure 1A-1J Shown are biolayer interferometry (BLI) titration data of TROP2 binding of non-mutated and mutated TROP2 binding domains (TBDs).
[0028] Figure 2A-2M Shown are BLI titration data of TROP2 binding of mutated TBDs.
[0029] Figure 3 Figure 2 shows the TROP2 binding curves and binding EC of non-mutated TBD and mutant TBD as measured by ELISA. 50 .
[0030] Figure 4 Figure 2 shows the TROP2 binding curves and binding EC of non-mutated TBD and mutant TBD as measured by ELISA. 50 .
[0031] Figure 5A-5D Shown are BLI titration data of TROP2 binding of non-mutated and mutated T cell engagers (TCEs).
[0032] Figure 6A-6D Shown are BLI titration data of TROP2 binding of non-mutated TCE and mutated TCE.
[0033] Figure 7 Figure 2 shows the TROP2 binding curve and binding EC of non-mutated TCE as measured by ELISA. 50 .
[0034] Figure 8 Figure 2 shows the CD3ε binding curve and binding EC of non-mutated TCE as measured by ELISA. 50 .
[0035] Fig. 9Figure 2 shows the TROP2 binding curves and binding EC of mutant TCEs as measured by ELISA. 50 .
[0036] Fig.10 Figure 2 shows the CD3ε binding curves and binding EC of mutant TCEs as measured by ELISA. 50 .
[0037] Fig.11 Figure 2 shows the TROP2 binding curves and binding EC of mutant TCEs as measured by ELISA. 50 .
[0038] Fig.12 Figure 2 shows the CD3ε binding curves and binding EC of mutant TCEs as measured by ELISA. 50 .
[0039] Figures 13A-13F Graph showing killing of TROP2-positive HCT116 tumor cells by TCE in the presence of CD8+ T cells.
[0040] Figure 14A-14F Graph showing killing of TROP2-positive MDAMB231 tumor cells by TCE in the presence of CD8+ T cells.
[0041] Figure 15A-15E Graph showing killing of TROP2-positive NCI-H292 tumor cells by TCE in the presence of CD8+ T cells.
[0042] Fig.16 Figure 2 shows the human CD3 binding curve and binding EC of TCE-9 to TCE-19 as measured by ELISA. 50 .
[0043] Fig.17 Figure 2 shows the human CD3 binding curves and binding EC of TCE-9 and TCE-20 to TCE-29 as measured by ELISA. 50 .
[0044] Fig.18 Figure 2 shows the human CD3 binding curves and binding EC of TCE-9 and TCE-30 to TCE-36 as measured by ELISA. 50 .
[0045] Fig.19 Figure 2 shows the binding curve and binding EC of TCE-37 to TCE-42 for CD3 binding as measured by ELISA. 50 .
[0046] Figure 20A-20BThe human CD3 ( Fig. 20A ) and cynomolgus monkey CD3 ( Fig. 20B ) Binding curves and binding EC 50 .
[0047] Fig.21 Figure 2 shows the TROP2 binding curves and binding EC of TCE-37, TCE-43, TCE-38, TCE-39 and TCE-40 as measured by ELISA. 50 .
[0048] Fig. 22 Graph showing CD3 binding curves and binding EC of TCE-37, TCE-43, TCE-38, TCE-39 and TCE-40 as measured by ELISA 50 .
[0049] Fig.23 Figure 2 shows the TROP2 binding curves and binding EC of TCE-42, TCE-45, TCE-46 and TCE-44 as measured by ELISA. 50 .
[0050] Fig.24 Figure 2 shows the CD3 binding curves and binding EC of TCE-42, TCE-45, TCE-46 and TCE-44 as measured by ELISA. 50 .
[0051] Figure 25A-Figure 25O Shown are sensorgrams of TCE-10 to TCE-24 binding to CD3ε as measured by biolayer interferometry (BLI).
[0052] Figure 26A-Figure 26N Shown are sensorgrams of TCE-25 to TCE-36 and TCE-9 binding to CD3ε as measured by BLI.
[0053] Figure 27A-Figure 27D Shown are sensorgrams of TCE-11, TCE-12, TCE-15 and TCE-34 binding to CD3ε as measured by BLI.
[0054] Figure 28A-28B Shown are sensorgrams of TCE-36 and TCE-9 binding to CD3ε as measured by BLI.
[0055] Figure 29A-29B Figure 3 shows the relationship between BLI and TROP2 ( Fig.29A ) and CD3ε( Fig.29B) Sensorgrams of TCE-37 bound to the molecule and the calculated binding affinity (K D ), association rate (k on ) and dissociation rate (k dis ).
[0056] Figure 30A-Figure 30B The graph shows TCE-38 binding to TROP2 as measured by BLI ( Fig. 30A ) and TCE-39( Fig. 30B )’s sensor diagram.
[0057] Figure 31A-Figure 31B Figure 3 shows TCE-38 binding to CD3ε as measured by BLI ( Fig.31A ) and TCE-39( Fig.31B )’s sensor diagram.
[0058] Figure 32A-32B Figure 3 shows the relationship between BLI and TROP2 ( Fig.32A ) and CD3ε( Fig.32B ) Sensorgram of bound TCE-40.
[0059] Figure 33A-Figure 33B Shown are sensorgrams of TCE-41 and TCE-42 binding to CD3ε as measured by BLI.
[0060] Figure 34A-Figure 34B Shown are sensorgrams of TCE-41 and TCE-42 binding to TROP2 as measured by BLI.
[0061] Figure 35A-Figure 35C Shown are sensorgrams of TCE-9, TCE-37, and TCE-43 binding to TROP2 as measured by BLI.
[0062] Fig.36 Graph showing killing of TROP2-positive NCI-H292 tumor cells by TCE in the presence of CD8+ T cells.
[0063] Fig.37 Graph showing killing of TROP2-positive NCI-H292 tumor cells by TCE in the presence of CD8+ T cells.
[0064] Fig.38 Graph showing killing of TROP2-positive NCI-H292 tumor cells by TCE in the presence of CD8+ T cells.
[0065] Fig.39 Graph showing killing of TROP2-positive HCT116 tumor cells by TCE in the presence of CD8+ T cells.
[0066] Fig.40 Graph showing killing of TROP2-positive NCI-H292 tumor cells by TCE in the presence of CD8+ T cells.
[0067] Fig.41 Graph showing killing of cynomolgus monkey TROP2-positive HEK293 cells by TCE in the presence of CD8+ T cells.
[0068] Fig.42 Graph showing killing of TROP2-positive NCI-H292 tumor cells by TCE in the presence of CD8+ T cells.
[0069] Fig.43 Graph showing killing of TROP2-positive NCI-H292 tumor cells by TCE in the presence of CD8+ T cells.
[0070] Fig.44 Graph showing killing of cynomolgus monkey TROP2-positive HEK293 cells by TCE in the presence of CD8+ T cells.
[0071] Fig.45 Graph showing killing of TROP2-positive NCI-H292 tumor cells by TCE in the presence of CD8+ T cells.
[0072] Fig.46 Graph showing killing of cynomolgus monkey TROP2-positive HEK293 cells by TCE in the presence of CD8+ T cells.
[0073] Fig.47 Graph showing killing of TROP2-positive NCI-H292 tumor cells by TCE in the presence of CD8+ T cells.
[0074] Fig.48 Graph showing killing of cynomolgus monkey TROP2-positive HEK293 cells by TCE in the presence of CD8+ T cells.
[0075] Fig.49 The results of the pharmacokinetic and toxicity studies of TCE-43 in cynomolgus monkeys are shown.
[0076] Fig.50 The results of the pharmacokinetic and toxicity studies of TCE-37 in cynomolgus monkeys are shown.
[0077] Fig.51 Shown is cytokine release in cynomolgus monkeys following continuous IV infusion of TCE-43.
[0078] Fig.52 Shown is cytokine release in cynomolgus monkeys following continuous IV infusion of TCE-37.
[0079] Figure 53A-53F Shown are clinical chemistry parameters in cynomolgus monkeys following continuous IV infusion of TCE-43.
[0080] Figure 54A-Figure 54F Shown are clinical chemistry parameters in cynomolgus monkeys following continuous IV infusion of TCE-37.
[0081] Fig.55 The results of the pharmacokinetic and toxicity studies of TCE-39 in cynomolgus monkeys are shown.
[0082] Fig.56 The results of the pharmacokinetic and toxicity studies of TCE-42 in cynomolgus monkeys are shown.
[0083] Fig.57 The results of the pharmacokinetic and toxicity studies of TCE-40 in cynomolgus monkeys are shown.
[0084] Figure 58A-Figure 58D Shown is cytokine release in cynomolgus monkeys following continuous IV infusion of TCE-39.
[0085] Figure 59A-Figure 59D Shown is cytokine release in cynomolgus monkeys following continuous IV infusion of TCE-42.
[0086] Fig.60 Shown is cytokine release in cynomolgus monkeys following continuous IV infusion of TCE-40.
[0087] Figure 61A-Figure 61F Shown are clinical chemistry parameters in cynomolgus monkeys following continuous IV infusion of TCE-39.
[0088] Figure 62A-62F Shown are clinical chemistry parameters in cynomolgus monkeys following continuous IV infusion of TCE-42.
[0089] Figure 63A-Figure 63F Shown are clinical chemistry parameters in cynomolgus monkeys following continuous IV infusion of TCE-40. DETAILED DESCRIPTION
[0090] TROP2 (also known as tumor-associated calcium signal transduction protein 2 or epithelial glycoprotein-1) is the protein product of the TACSTD2 gene and is a transmembrane glycoprotein that plays a role in a variety of cell signaling pathways, many of which are associated with tumorigenesis. TROP2 has been shown to be overexpressed in a variety of human cancers, including lung cancer, breast cancer, cervical cancer, ovarian cancer, colorectal cancer, pancreatic cancer and gastric cancer, and its expression is associated with poor patient prognosis. In addition, TROP2 acts as an oncogene that can drive tumorigenesis and metastasis in epithelial cancers such as colorectal cancer. TROP2 expression in cancer cells has long been associated with drug resistance, and high levels of TROP2 expression have been shown to be associated with poor prognosis in a variety of cancer types. In a co-analysis (meta-analysis) of data including from approximately 2,500 patients, increased TROP2 expression was associated with poor overall survival and disease-free survival outcomes in several solid tumors.
[0091] Disclosed herein are recombinant antibodies or antigen-binding fragments thereof comprising a tumor-associated calcium signaling protein 2 (TROP2) binding domain that has been optimized for certain properties. In some embodiments, the TROP2 binding domain has TROP2 binding properties that improve safety and reduce accumulation in healthy tissues. For example, in some embodiments, the TROP2 binding domain has a faster dissociation rate (k diss ) and / or weaker (higher) EC 50 , which can help reduce accumulation in healthy tissues. In addition, in some embodiments, the TROP2 binding domain has a faster dissociation rate (k diss ) and / or weaker (higher) EC 50 , while maintaining TROP2 binding ability and activity. In some embodiments, the recombinant antibody or antigen-binding fragment thereof exhibits weaker cytotoxic activity to help reduce off-tumor on-target toxicity in healthy tissues.
[0092] Disclosed herein are recombinant antibodies or antigen-binding fragments thereof comprising a tumor-associated calcium signaling protein 2 (TROP2) binding domain that have been optimized by alanine scanning mutagenesis. Alanine scanning is performed on the TROP2 binding domain to optimize certain properties of the recombinant antibody or its antigen-binding fragment. Alanine scanning is performed by systematically mutating individual residues to alanine in the TROP2 binding domain relative to a non-mutated or "wild-type" TROP2 binding domain. Specifically, residues in the third complementarity determining region (CDR3) of an immunoglobulin light chain and an immunoglobulin heavy chain are systematically mutated to alanine to establish a CDR3-related structure activity relationship (SAR) and identify a TROP2 binding domain that exhibits a faster dissociation rate to reduce accumulation in healthy tissues while maintaining binding and activity.
[0093] In some embodiments, a recombinant antibody or antigen fragment comprising a TROP2 binding domain that has been optimized for certain properties further comprises a CD3 binding domain. Multispecific antibodies for redirecting T cells to cancer have shown promise in both preclinical and clinical studies. The method relies on the binding of an antigen-interacting portion of the antibody to a tumor-associated antigen or marker (such as TROP2), while a second antigen-interacting portion can bind to an effector cell antigen (such as CD3) on T cells, which then triggers cytotoxic activity. Disclosed herein is a multispecific antibody composition targeting TROP2 and CD3 for triggering cytotoxic activity.
[0094] In some embodiments, the recombinant antibodies or antigen-binding fragments thereof described herein are used in methods for treating cancer. In some embodiments, cancer has cells expressing TROP2. In some cases, cancer is a solid tumor cancer. In some embodiments, cancer is lung cancer, breast cancer (eg, HER2+; ER / PR+; TNBC), cervical cancer, ovarian cancer, colorectal cancer, pancreatic cancer, or gastric cancer. In some embodiments, the polypeptides or polypeptide complexes described herein are used in methods for treating triple-negative breast cancer (TNBC), urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, esophageal cancer, head and neck cancer, prostate cancer, or endometrial cancer. In some embodiments, the polypeptides or polypeptide complexes described herein are used in methods for treating breast cancer, lung cancer, urothelial carcinoma, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, head and neck cancer, and glioma.
[0095] Some definitions
[0096] The terms used herein are only used for the purpose of describing a particular situation and are not intended to be limiting. As used herein, the singular forms "a, an," and "the" are also intended to include the plural forms unless the context clearly indicates otherwise. In addition, with respect to the terms "including / includes," "having / has," "with," or variations thereof used in the specific embodiments and / or claims, these terms are intended to be inclusive in a manner similar to the term "comprising."
[0097] The term "antibody" is used in the broadest sense to cover fully assembled antibodies; antibody fragments that can bind antigen, such as Fab, F(ab')2, Fv; single-chain antibodies (scFv); diabodies; antibody chimeras; hybrid antibodies; bispecific antibodies, etc.
[0098] The term "complementarity determining region" or "CDR" is a segment of an antibody variable region that is structurally complementary to the epitope to which the antibody binds and is more variable than the rest of the variable region. Therefore, CDRs are sometimes referred to as hypervariable regions. The variable region contains three CDRs. CDR peptides can be obtained by constructing genes encoding the CDRs of the antibody of interest. For example, these genes are prepared by synthesizing the variable regions from RNA of cells producing the antibody using the polymerase chain reaction. See, for example, Larrick et al., Methods: A Companion to Methods in Enzymology 2: 106 (1991); Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (Eds.), pp. 166-179 (Cambridge University Press 1995). Monoclonal Antibodies"; and Ward et al., "Genetic Manipulation and Expression of Antibodies", in Monoclonal Antibodies: Principles and Applications, Birch et al., (Eds.), pp. 137-185 (Wiley-Liss, Inc. 1995).
[0099] The term "Fab" refers to a protein containing a light chain constant domain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab' fragments in that a few residues are added to the carboxyl terminus of the heavy chain CH1 domain, including one or more cysteines from the antibody hinge region. Fab'-SH is referred to herein as Fab', in which the cysteine residues of the constant domains carry a free thiol group. Fab' fragments are produced by reducing the heavy chain disulfide bonds of the F(ab')2 fragment. Other chemical couplings of antibody fragments are also known.
[0100] "Single chain variable fragment (scFv)" is a fusion protein of the variable regions of the heavy chain (VH) and light chain (VL) of an antibody, connected by a short linker peptide of ten to about 25 amino acids. For flexibility, the linker is usually rich in glycine, and for solubility, the linker is usually rich in serine or threonine, and the N-terminus of VH can be connected to the C-terminus of VL, and vice versa. The protein retains the specificity of the original antibody, despite the removal of the constant region and the introduction of the linker. scFv antibodies are described, for example, in Houston, JS, Methods in Enzymol. 203 (1991) 46-96). In addition, the antibody fragment comprises a single chain polypeptide having the characteristics of a VH domain, i.e., being able to be assembled with a VL domain, or having the characteristics of a VL domain, i.e., being able to be assembled with a VH domain to form a functional antigen binding site, thereby providing the antigen binding properties of a full-length antibody.
[0101] As used herein, the term "percentage (%) amino acid sequence identity" about a sequence is defined as, after comparing sequences and introducing room (if necessary) to realize maximum percentage sequence identity and not considering any conservative substitution as a part for sequence identity, the percentage of the amino acid residue identical with the amino acid residue in the specific sequence in the candidate sequence. The comparison for determining percentage amino acid sequence identity can be realized in a variety of ways known to those skilled in the art, for example, using publicly available computer software such as EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for measuring the comparison, including any algorithm required for maximum comparison on the total length of the sequence compared.
[0102] In the case of amino acid sequence comparison using ALIGN-2, the % amino acid sequence identity of a given amino acid sequence A with, and, or to a given amino acid sequence B (which can alternatively be expressed as a given amino acid sequence A having or comprising a certain % amino acid sequence identity with, and, or to a given amino acid sequence B) is calculated as follows: 100 multiplied by a fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in the program alignment of A and B, and where Y is the total number of amino acid residues in B. It should be understood that when the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program as described in the preceding paragraph.
[0103] The terms "complementarity determining region" and "CDR", which are synonymous with "hypervariable region" or "HVR", are known in the art to refer to non-contiguous sequences of amino acids within an antibody variable region that confer antigen specificity and / or binding affinity. Typically, there are three CDRs (CDR-H1, CDR-H2, CDR-H3) in each heavy chain variable region and three CDRs (CDR-L1, CDR-L2, CDR-L3) in each light chain variable region. "Framework region" and "FR" are known in the art and refer to the non-CDR portions of the heavy and light chain variable regions. Typically, there are four FRs (FR-H1, FR-H2, FR-H3, and FR-H4) in each full-length heavy chain variable region, and four FRs (FR-L1, FR-L2, FR-L3, and FR-L4) in each full-length light chain variable region.The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described in Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding sitetopography," J. Mol. Biol. 262, 732-745. ("Contact" numbering scheme); Lefranc MP et al., "IMGTunique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev Comp Immunol, 2003 Jan; 27 (1): 55-77 ("IMGT" numbering scheme); Honegger A and Plückthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool," J Mol Biol, 2001 Jun 8; 309 (3): 657-70, ("Aho" numbering scheme); and Whitelegg NR and Rees AR, "WAM: an improved algorithm for modelling antibodies on the WEB," Protein Eng. 2000 Dec; 13 (12): 819-24 ("AbM" numbering scheme). In certain embodiments, the CDRs of the antibodies described herein can be defined by a method selected from Kabat, Chothia, IMGT, Aho, AbM, or a combination thereof.
[0104] The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignments, while the Chothia scheme is based on structural information. The numbering of the Kabat and Chothia schemes is based on the most common antibody region sequence lengths, wherein insertions are accommodated by inserting letters, such as "30a", and deletions occur in some antibodies. These two schemes place certain insertions and deletions ("indels") in different positions, resulting in different numbering. The Contact scheme is based on the analysis of complex crystal structures, and is similar to the Chothia numbering scheme in many respects.
[0105] Recombinant antibody or antigen-binding fragment composition
[0106] TROP2 binding domain
[0107] Disclosed herein is a recombinant antibody or antigen-binding fragment thereof comprising a tumor-associated calcium signal transducer protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 1, wherein CDR2-L comprises the amino acid sequence of SEQ ID NO: 2, NO:2, and wherein CDR3-L comprises the amino acid sequence of X1X2HYX3XXXX6X7, wherein X1 is Q, S, T, D, N, E, H, R, K or A, X2 is Q, S, T, D, N, E, H, K, R or A, X3 is I, G, P, V, L, M, S, T or A, X4 is T, G, S, M, H, N, Q or A, X5 is P, G, V, L, I, M, S, T or A, X6 is L, G, P, V, I, M, S, T or A; and X7 is T, G, S, M, H, N, Q or A, wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:13, wherein CDR2-H comprises the amino acid sequence of SEQ ID NO:14, and wherein CDR3-H comprises AX8X9GX 10 X 11 X 12 X 13 YW 14 X 15 X 16 X 17 The amino acid sequence of wherein X8 is R, S, T, Q, D, E, N, H, K or A, X9 is G, P, V, L, I, M, S, T or A, X 10 is F, Y, W, V, L, I, G or A, X 11is G, P, V, L, I, M, S, T or A, X 12 is S, G, T, M, N, Q, H or A, X 13 is S, G, T, M, N, Q, H or A, X 14 is Y, F, W, V, L, I, G or A, X 15 is F, Y, W, V, L, I, G or A, X 16 is D, Q, N, E, S, T, H, K, R, or A, and X 17 is V, G, P, L, I, M, S, T or A, and wherein when CDR3-H comprises the amino acid sequence of SEQ ID NO: 15, CDR3-L does not comprise the amino acid sequence of SEQ ID NO: 3.
[0108] In some embodiments, X1 is Q, N, D, E or A, X2 is Q, N, D, E or A, X3 is I, V, L or A, X4 is T, S or A, X5 is P, G or A, X6 is L, V, I or A, X7 is T, S or A, X8 is R, K or A, X9 is G, S, T or A, X 10 is F, Y or A, X 11 is G, S, T or A, X 12 is S, G, T or A, X 13 is S, G, T or A, X 14 is Y, W, F or A, X 15 is F, Y, W or A, X 16 is D, E, Q, N, or A, and X 17 is V, L, I or A. In some embodiments, X1 is Q, and X6 is L. In some embodiments, X8 is R, X 10 It's F, X 11 It's G, X 14 It is Y, X 15 is F, and X 16 It is D.
[0109] In some embodiments, X1 is Q, S, T, D, N, E, or A; X2 is Q, S, T, D, N, E, or A; X3 is I, G, P, V, L, M, or A; X4 is T, G, S, M, H, N, Q, or A; X5 is P, G, V, L, I, M, or A; X6 is L, G, P, V, I, M, or A; X7 is T, G, S, M, H, N, Q, or A; X8 is R, H, K, or A; X9 is G, P, V, L, I, M, S, T, or A; X 10 is F, Y, W, V, L, I or A; X 11 is G, P, V, L, I, M, S, T, or A; X 12 is S, G, T, M, N, Q or A; X13 is S, G, T, M, N, Q or A; X 14 is Y, F, W, V, L, I or A; X 15 is F, Y, W, V, L, I or A; X 16 is D, Q, N, E, S, T, or A; and X 17 is V, G, P, L, I, M or A. In some embodiments, X1 is Q, N or A; X2 is Q, N or A; X3 is I, V, L or A; X4 is T, S or A; X5 is P, G or A; X6 is L, V, I or A; X7 is T, S or A; X8 is R, K or A; X9 is G, V, S, T or A; X 10 is F, Y or A; X 11 is G, V, S, T or A; X 12 is S, G, T or A; X 13 is S, G, T or A; X 14 is Y, W or A; X 15 is F, Y or A; X 16 is D, E, or A; and X 17 is V, G, L, I or A. In some embodiments, X1 is QA and X6 is L. In some embodiments, X8 is R; X 10 It is F;X 11 It is G; X 14 It is Y; X 15 is F; and X 16 It is D.
[0110] In some embodiments, CDR3-L comprises an amino acid selected from SEQ ID NOs: 3-5 and 8-12. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2; CDR3-L: SEQ ID NO: 8 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15. NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:10 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:11 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; and CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 12 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15.
[0111] In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 8 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 9 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 10 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 11 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15.In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 12 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15.
[0112] In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 8 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 9 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15. NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:10 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:12 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15.
[0113] In some embodiments, CDR3-H comprises an amino acid selected from SEQ ID NOs: 16-17, 19-22, 25-28. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 16; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17. NO:19; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:20; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:22; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 25;CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:26; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:27; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:28.;
[0114] In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 16. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 19. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 20. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 21. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 22.In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 25. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 26. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 27. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a CDR sequence set including CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 28.
[0115] In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 21; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 21. NO:22; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:28.
[0116] Disclosed herein is a recombinant antibody or antigen-binding fragment thereof comprising a tumor-associated calcium signaling protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the following: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5, and CDR1-H: SEQ ID NO: 6; ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:6 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:7 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:8 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 10 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15;CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:11, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:12, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:16; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:17; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:18; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:19; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:20; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21;CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:22; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:23; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:24; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:25; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:26; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:27; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:28. ;
[0117] Table 1. TROP2 binding domain light chain complementarity determining regions (CDRs) based on the IMGT CDR numbering system.
[0118]
[0119] Table 2. TROP2 binding domain heavy chain complementarity determining regions (CDRs) based on the IMGT CDR numbering system.
[0120] Construct description Amino acid sequence (N to C) SEQ ID NO: CDR1-H GYTFTNYG 13 CDR2-H INTYTGEP 14 CDR3-H ARGGFGSSYWYFDV 15 CDR3-H R98A AAGGFGSSYWYFDV 16 CDR3-H G99A ARAGFGSSYWYFDV 17 CDR3-H G100A ARGAFGSSYWYFDV 18 CDR3-H F101A ARGGAGSSYWYFDV 19 CDR3-H G102A ARGGFASSYWYFDV 20 CDR3-H S103A ARGGFGASYWYFDV 21 CDR3-H S104A ARGGFGSAYWYFDV 22 CDR3-H Y105A ARGGFGSSAWYFDV 23 CDR3-H W106A ARGGFGSSYAYFDV 24 CDR3-HY107A ARGGFGSSYWAFDV 25 CDR3-H F108A ARGGFGSSYWYADV 26 CDR3-HD109A ARGGFGSSYWYFAV 27 CDR3-H V110A ARGGFGSSYWYFDA 28
[0121] In some embodiments, the TROP2 binding domain comprises Fab, Fab', (Fab')2 or a single chain variable fragment (scFv). In some embodiments, the TROP2 binding domain is Fab. In some embodiments, the immunoglobulin light chain comprises the variable domain of an immunoglobulin K (IgK) or immunoglobulin λ (IgL) light chain. In some embodiments, the immunoglobulin heavy chain comprises the variable domain of an IgG1, IgG2, IgG3 or IgG4 heavy chain.
[0122] In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, or 73. In some embodiments, the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, or 74.
[0123] In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 31, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 32. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 33, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 34. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 35, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 36. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 37, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 38. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 39, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 40. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 42. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:43, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:44.In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 45, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 46. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 47, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 48.
[0124] In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 49, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 50. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 51, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 52. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 53, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 54. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 55, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 56. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 57, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 60. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:61, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:62.In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 63, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 64. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 65, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 66. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 67, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 68. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 69, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 70. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 71, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 72. In some embodiments, the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 73, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 74.
[0125] Table 3. TROP2 binding domain (TBD) heavy chain and light chain sequences
[0126]
[0127]
[0128]
[0129]
[0130]
[0131]
[0132] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 31, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 32.
[0133] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 33, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 34.
[0134] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 8 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 39, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 40.
[0135] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 9 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 41, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 42.
[0136] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 10 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 43, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 44.
[0137] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 11 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 45, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 46.
[0138] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 12 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 47, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 48.
[0139] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 16; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 49, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 50.
[0140] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 51, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 52.
[0141] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 19; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 55, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 56.
[0142] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 20; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 57, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 58.
[0143] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 21; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 59, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 60.
[0144] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 22; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 61, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 62.
[0145] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 25; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 67, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 68.
[0146] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 26; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 69, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 70.
[0147] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 27; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 71, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 72.
[0148] In some embodiments, the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the amino acid sequence includes CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 28; and the immunoglobulin light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 73, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 74.
[0149] In some embodiments, the TROP2 binding domain has a faster dissociation rate (greater k) for TROP2 binding as compared to a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO: 29 and an immunoglobulin heavy chain according to SEQ ID NO: 30, as measured under substantially similar kinetic assay conditions. diss In some embodiments, the TROP2 binding domain has weaker binding to TROP2 than a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO: 29 and an immunoglobulin heavy chain according to SEQ ID NO: 30, as measured by an enzyme-linked immunosorbent assay (ELISA) under substantially similar assay conditions. In some embodiments, the TROP2 binding domain has an increased EC for TROP2 as measured by an ELISA under substantially similar assay conditions compared to a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO: 29 and an immunoglobulin heavy chain according to SEQ ID NO: 30. 50 In some embodiments, TROP2 comprises the amino acid sequence according to SEQ ID NO: 100 (see Table 10).
[0150] CD3 binding domain
[0151] In some embodiments, the recombinant antibody or antigen binding fragment further comprises a CD3 binding domain. In some embodiments, the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprises complementary determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 75, wherein CDR2-L comprises the amino acid sequence of SEQ ID NO: 76, wherein CDR3-L comprises the amino acid sequence of SEQ ID NO: 77, wherein CDR1-H comprises the amino acid sequence of SEQ ID NO: 78, wherein CDR2-H comprises the amino acid sequence of SEQ ID NO: 79, and wherein CDR3-H comprises the amino acid sequence of SEQ ID NO: 80.
[0152] In some embodiments, the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementary determining regions (CDRs) CDR1-L, CDR2-L, and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H, and CDR3-H; wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 75; wherein CDR2-L comprises the amino acid sequence of SEQ ID NO: NO:76 amino acid sequence; wherein CDR3-L comprises the amino acid sequence of Z1-Z2-W-Z3-Z4-Z5-Z6-W-Z7-Z8; wherein Z1 is V, G, P, L, I, M, S, T or A; Z2 is L, G, P, V, I, M, S, T or A; Z3 is Y, F, W, V, L, I, G or A; Z4 is S, G, T, M, N, Q, H or A; Z5 is N, Q, S, T, D, E, H, K, R or A; Z6 is R, S, T, Q, D, E, H, K, N or A; Z7 is V, G, P, L, I, M, S, T or A; and Z8 is F, Y, W, V, L, I, G or A; wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:78; wherein CDR2-H comprises SEQ ID NO:79 amino acid sequence; wherein CDR3-H comprises Z9-Z 10 -Z 11 -Z 12 -NZ 13 -Z 14 -Z 15 -Z 16 -Z 17 -Z 18 -Z 19 -YZ 20 -AZ 21wherein Z9 is V, G, P, L, I, M, S, T or A; 10 is R, S, T, Q, D, E, H, K, N, or A; Z 11 is H, R, K, G, T, S, N, Q or A; Z 12 is G, P, V, L, I, M, S, T, or A; Z 13 is F, Y, W, V, L, I, G or A; Z 14 is G, P, V, L, I, M, S, T, or A; Z 15 is N, Q, S, T, D, E, H, K, R or A; Z 16 is S, G, T, M, N, Q, H or A; Z 17 is Y, F, W, V, L, I, G or A; Z 18 is I, G, P, V, L, M, S, T, or A; Z 19 is S, G, T, M, N, Q, H or A; Z 20 is W, F, Y, V, L, I, G, or A; and Z 21 is Y, F, W, V, L, I, G, or A. In some embodiments, Z1 is V, G, L, I, or A; Z2 is L, V, I, or A; Z3 is Y, W, F, or A; Z4 is S, G, T, or A; Z5 is N, Q, D, E, or A; Z6 is R, K, or A; Z7 is V, G, L, I, or A; Z8 is F, Y, W, or A; Z9 is V, G, L, I, or A; Z 10 is R, K or A; Z 12 is G, S, T or A; Z 13 is F, Y, W or A; Z 14 is G, S, T or A; Z 15 is N, Q, D, E or A; Z 16 is S, G, T or A; Z 17 is Y, W, F or A; Z 18 is I, V, L or A; Z 19 is S, G, T or A; Z 20 is W, Y, F or A; and Z 21 is Y, W, F or A. In some embodiments, Z8 is F. In some embodiments, Z 10 It is R; Z 11 It is H; Z 13 It is F; Z 18 It is I; Z 19 is S; and Z 20 It's W.
[0153] In some embodiments, CDR3-L comprises an amino acid sequence selected from SEQ ID NOs: 77, 105-106, 108-111, and 113-114. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 105 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 106 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 108 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80. NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80;and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:114 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 105 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 106 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 108 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80. NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80;and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80.;
[0154] In some embodiments, CDR3-H comprises an amino acid sequence selected from SEQ ID NOs: 80, 116-119, 121-127, and 129-130. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 116; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 117; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 117. NO:79, CDR3-H: SEQ ID NO:118; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:121; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:125; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:126; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:127; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:129; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:130. In some embodiments, the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 116;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ IDNO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ IDNO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:125; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ IDNO:79, CDR3-H: SEQ ID NO:130.;
[0155] In some embodiments, the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L, and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H, and CDR3-H, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 105, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 106, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 80. ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:107 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:108 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:112, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:114, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:116; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:117; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:118; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:120;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:121; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ IDNO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ IDNO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQID NO:125; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:126; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ IDNO:79, CDR3-H: SEQ ID NO:127; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:128;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:129; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:130. ;
[0156] In some embodiments, the immunoglobulin light chain of the CD3 binding domain comprises the variable domain of an immunoglobulin kappa (IgK) or immunoglobulin lambda (IgL) light chain. In some embodiments, the immunoglobulin heavy chain of the CD3 binding domain comprises the variable domain of an IgG1, IgG2, IgG3 or IgG4 heavy chain.
[0157] Table 4. CD3 binding domain light chain complementarity determining regions (CDRs) based on the IMGT CDR numbering system.
[0158] Construct description Amino acid sequence (N to C) SEQ ID No: CDR1-L TGAVTSGNY 75 CDR2-L GT 76 CDR3-L VxV 77 CDR1-L TGAVTSANY 104 CDR3-L V231A ALWYSNRWV 105 CDR3-L L232A VAWYSNRWV 106 CDR3-L W233A VLAYSNRWV 107 CDR3-L Y234A VWV 108 CDR3-L S235A VxV 109 CDR3-L N236A VxV 110 CDR3-L R237A VLWYSNAW 111 CDR3-L W238A VLWYSNRAV 112 CDR3-L V239A VxW 113 CDR3-L F240A VLWYSNRWVA 114
[0159] Table 5. CD3 binding domain heavy chain complementarity determining regions (CDRs) based on the IMGT CDR numbering system.
[0160]
[0161]
[0162] In some embodiments, the immunoglobulin light chain of the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 81. In some embodiments, the immunoglobulin heavy chain of the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 82. In some embodiments, the immunoglobulin light chain of the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 81, and the immunoglobulin heavy chain of the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 82. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 99. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 99. In some embodiments, the CD3 binding domain comprises a Fab, Fab', (Fab')2 or a single chain variable fragment (scFv). In some embodiments, the CD3 binding domain is a scFv.
[0163] In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 131. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 132. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 133. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 136. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 137. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 138. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 139. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 140. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 141. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 142. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:143.In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 144. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 145. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 146. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 147. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 148. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 149. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 150. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 151. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 152. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 153. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 154. In some embodiments, the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 155.
[0164] Table 6. CD3 heavy and light chain sequences and scFv
[0165]
[0166]
[0167]
[0168]
[0169]
[0170] In some embodiments, the N-terminus of the immunoglobulin heavy chain of the TROP2 binding domain binds to the C-terminus of the immunoglobulin light chain of the CD3 binding domain. In some embodiments, the C-terminus of the immunoglobulin heavy chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin light chain of the CD3 binding domain. In some embodiments, the N-terminus of the immunoglobulin heavy chain of the TROP2 binding domain binds to the C-terminus of the immunoglobulin heavy chain of the CD3 binding domain. In some embodiments, the C-terminus of the immunoglobulin heavy chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin heavy chain of the CD3 binding domain. In some embodiments, the N-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the C-terminus of the immunoglobulin light chain of the CD3 binding domain. In some embodiments, the C-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin light chain of the CD3 binding domain. In some embodiments, the C-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin light chain of the CD3 binding domain. In some embodiments, the N-terminus of the immunoglobulin light chain of the TROP2 binding domain is bound to the C-terminus of the immunoglobulin heavy chain of the CD3 binding domain. In some embodiments, the C-terminus of the immunoglobulin light chain of the TROP2 binding domain is bound to the N-terminus of the immunoglobulin heavy chain of the CD3 binding domain.
[0171] In some embodiments, the CD3 binding domain includes Fab, Fab', (Fab')2 or a single chain variable fragment (scFv). In some embodiments, the CD3 binding domain is a scFv. In some embodiments, the CD3 binding domain is a scFv and the TROP2 binding domain is a Fab or Fab'. In some embodiments, the scFv binds to the immunoglobulin heavy chain of Fab or Fab'. In some embodiments, the scFv binds to the immunoglobulin light chain of Fab or Fab'. In some embodiments, the immunoglobulin light chain of scFv binds to the immunoglobulin heavy chain of Fab or Fab'. In some embodiments, the immunoglobulin light chain of scFv binds to the immunoglobulin light chain of Fab or Fab'. In some embodiments, the immunoglobulin light chain of scFv binds to the immunoglobulin light chain of Fab or Fab'. In some embodiments, the immunoglobulin heavy chain of scFv binds to the immunoglobulin heavy chain of Fab or Fab'.
[0172] T cell engager sequences
[0173] In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 87 and SEQ ID NO: 88. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 89 and SEQ ID NO: 90. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 91 and SEQ ID NO: 92. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 93 and SEQ ID NO: 94. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 95 and SEQ ID NO: 96. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97 and SEQ ID NO: 98.
[0174] In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 188. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 189. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 190. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 194. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 195. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 158 and SEQ ID NO: 196.
[0175] In some embodiments, the recombinant antibody or antigen-binding fragment thereof has weaker cytotoxic activity than a recombinant antibody or antigen-binding fragment thereof comprising an immunoglobulin light chain according to SEQ ID NO: 83 or 85 and an immunoglobulin heavy chain according to SEQ ID NO: 84 or 86, as measured in an in vitro tumor cell killing assay under substantially similar assay conditions.
[0176] In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises a modified amino acid or a non-natural amino acid, or a modified non-natural amino acid, or a combination thereof. In some embodiments, the modified amino acid or the modified non-natural amino acid comprises a post-translational modification. In some embodiments, P1, P2, or P 1a or P1, P2 and P 1aModifications included include, but are not limited to, acetylation, acylation, ADP ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer RNA-mediated addition of amino acids to proteins (such as arginylation and ubiquitination). The recombinant antibodies or antigen-binding fragments thereof are modified anywhere, including the peptide backbone, amino acid side chains, and termini.
[0177] Table 7. TROP2-T cell engager (TCE) sequences
[0178]
[0179]
[0180]
[0181]
[0182] Table 8. TROP2-T cell engager (TCE) sequences
[0183]
[0184]
[0185]
[0186]
[0187]
[0188]
[0189]
[0190]
[0191]
[0192]
[0193]
[0194]
[0195]
[0196] Polypeptides encoding recombinant antibody or antigen-binding fragment compositions
[0197] In some embodiments, disclosed herein is an isolated recombinant nucleic acid molecule encoding a recombinant antibody or antigen-binding fragment thereof comprising a tumor-associated calcium signaling protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L, and CDR3-L, the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H, and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 1, wherein CDR2-L comprises the amino acid sequence of SEQ ID NO: 2. NO:2, and wherein CDR3-L comprises the amino acid sequence of X1X2HYX3X4X5XXXX7, wherein X1 is Q, S, T, D, N, E, H, R, K or A, X2 is Q, S, T, D, N, E, H, K, R or A, X3 is I, G, P, V, L, M, S, T or A, X4 is T, G, S, M, H, N, Q or A, X5 is P, G, V, L, I, M, S, T or A, X6 is L, G, P, V, I, M, S, T or A, and X7 is T, G, S, M, H, N, Q or A, wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:13, wherein CDR2-H comprises the amino acid sequence of SEQ ID NO:14, and wherein CDR3-H comprises AX8X9GX 10 X 11 X 12 X13W 14 X 15 X 16 X 17 The amino acid sequence of wherein X8 is R, S, T, Q, D, E, N, H, K or A, X9 is G, P, V, L, I, M, S, T or A, X 10 is F, Y, W, V, L, I, G or A, X 11 is G, P, V, L, I, M, S, T or A, X 12 is S, G, T, M, N, Q, H or A, X 13 is S, G, T, M, N, Q, H or A, X 14 is Y, F, W, V, L, I, G or A, X 15 is F, Y, W, V, L, I, G or A, X 16 is D, Q, N, E, S, T, H, K, R, or A, and X 17is V, G, P, L, I, M, S, T or A, and wherein when CDR3-H comprises the amino acid sequence of SEQ ID NO: 15, CDR3-L does not comprise the amino acid sequence of SEQ ID NO: 3. In some embodiments, X1 is Q, S, T, D, N, E or A; X2 is Q, S, T, D, N, E or A; X3 is I, G, P, V, L, M or A; X4 is T, G, S, M, H, N, Q or A; X5 is P, G, V, L, I, M or A; X6 is L, G, P, V, I, M or A; X7 is T, G, S, M, H, N, Q or A; X8 is R, H, K or A; X9 is G, P, V, L, I, M, S, T or A; X 10 is F, Y, W, V, L, I or A; X 11 is G, P, V, L, I, M, S, T, or A; X 12 is S, G, T, M, N, Q or A; X 13 is S, G, T, M, N, Q or A; X 14 is Y, F, W, V, L, I or A; X 15 is F, Y, W, V, L, I or A; X 16 is D, Q, N, E, S, T, or A; and X 17 It is V, G, P, L, I, M or A.
[0198] In some embodiments, the present invention further discloses an isolated recombinant nucleic acid molecule encoding a recombinant antibody or antigen-binding fragment thereof comprising a tumor-associated calcium signaling protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the following: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; NO:2, CDR3-L: SEQ ID NO:5 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:6 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:7 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:8 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15;CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:10, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:11, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:12, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:16; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:17; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:18; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:19; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:20; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2;CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2; CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14; CDR3-H: SEQ ID NO:22; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:23; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:24; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:25; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:26; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:27; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:28.;
[0199] Pharmaceutical composition
[0200] In some embodiments, disclosed herein is a pharmaceutical composition comprising: (a) a recombinant antibody or antigen-binding fragment thereof as described herein and (b) a pharmaceutically acceptable excipient. In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises a tumor-associated calcium signal transducer 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprises complementary determining regions (CDRs) CDR1-L, CDR2-L, and CDR3-L, the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H, and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 1, wherein CDR2-L comprises the amino acid sequence of SEQ ID NO: 2. NO:2, and wherein CDR3-L comprises the amino acid sequence of X1X2HYX3X4X5XXXX7, wherein X1 is Q, S, T, D, N, E, H, R, K or A, X2 is Q, S, T, D, N, E, H, K, R or A, X3 is I, G, P, V, L, M, S, T or A, X4 is T, G, S, M, H, N, Q or A, X5 is P, G, V, L, I, M, S, T or A, X6 is L, G, P, V, I, M, S, T or A, and X7 is T, G, S, M, H, N, Q or A, wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:13, wherein CDR2-H comprises the amino acid sequence of SEQ ID NO:14, and wherein CDR3-H comprises AX8X9GX 10 X 11 X 12 X13W 14 X 15 X 16 X 17 The amino acid sequence of wherein X8 is R, S, T, Q, D, E, N, H, K or A, X9 is G, P, V, L, I, M, S, T or A, X 10 is F, Y, W, V, L, I, G or A, X 11 is G, P, V, L, I, M, S, T or A, X 12 is S, G, T, M, N, Q, H or A, X 13 is S, G, T, M, N, Q, H or A, X 14 is Y, F, W, V, L, I, G or A, X 15 is F, Y, W, V, L, I, G or A, X 16 is D, Q, N, E, S, T, H, K, R, or A, and X 17is V, G, P, L, I, M, S, T or A, and wherein when CDR3-H comprises the amino acid sequence of SEQ ID NO: 15, CDR3-L does not comprise the amino acid sequence of SEQ ID NO: 3. In some embodiments, X1 is Q, S, T, D, N, E or A; X2 is Q, S, T, D, N, E or A; X3 is I, G, P, V, L, M or A; X4 is T, G, S, M, H, N, Q or A; X5 is P, G, V, L, I, M or A; X6 is L, G, P, V, I, M or A; X7 is T, G, S, M, H, N, Q or A; X8 is R, H, K or A; X9 is G, P, V, L, I, M, S, T or A; X 10 is F, Y, W, V, L, I or A; X 11 is G, P, V, L, I, M, S, T, or A; X 12 is S, G, T, M, N, Q or A; X 13 is S, G, T, M, N, Q or A; X 14 is Y, F, W, V, L, I or A; X 15 is F, Y, W, V, L, I or A; X 16 is D, Q, N, E, S, T, or A; and X 17 It is V, G, P, L, I, M or A.
[0201] In some embodiments, the recombinant antibody or antigen-binding fragment thereof comprises a tumor-associated calcium signaling protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L, and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H, and CDR3-H, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the following: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5, and CDR1-H: SEQ ID NO: 6 ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:6 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:7 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:8 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 10 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15;CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:11, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:12, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:16; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:17; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:18; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:19; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:20; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2; CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2;CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14; CDR3-H: SEQ ID NO:22; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:23; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:24; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:25; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:26; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:27; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:28.;
[0202] For administration to a subject, a recombinant antibody or antigen-binding fragment thereof as disclosed herein can be provided in a pharmaceutical composition together with one or more pharmaceutically acceptable carriers or excipients. The term "pharmaceutically acceptable carrier" includes, but is not limited to, any carrier that does not interfere with the effectiveness of the biological activity of the component and is non-toxic to the patient to which it is administered. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions such as oil / water emulsions, various types of wetting agents, sterile solutions, and the like. Such carriers can be prepared by conventional methods and can be administered to a subject at a suitable dose. Preferably, the composition is sterile. These compositions can also contain adjuvants such as preservatives, emulsifiers, and dispersants. Protection against the effects of microorganisms can be ensured by including various antibacterial and antifungal agents.
[0203] The pharmaceutical composition can be in any suitable form (depending on the desired method of administration). It can be provided in unit dosage form, can be provided in a sealed container and can be provided as part of a kit. Such a kit can include instructions for use. It can include a plurality of said unit dosage forms.
[0204] The pharmaceutical composition can be adapted for administration by any suitable route, including parenteral (e.g., subcutaneous, intramuscular or intravenous) routes. Such compositions can be prepared by any method known in the pharmaceutical art, for example, by mixing the active ingredient with a carrier or excipient under sterile conditions.
[0205] Dosages of the substances of the present disclosure may vary within wide ranges, depending on the disease or disorder to be treated, the age and condition of the individual to be treated, etc., and the physician will ultimately determine the appropriate dosage to be used.
[0206] Treatment
[0207] In some embodiments, it is a method of treating cancer in a subject in need, comprising administering to the subject a recombinant antibody or antigen-binding fragment thereof as described herein. In some embodiments, the cancer has cells expressing TROP2. In some cases, the cancer is a solid tumor cancer. In some embodiments, the cancer is lung cancer, breast cancer (e.g., HER2+; ER / PR+; TNBC), cervical cancer, ovarian cancer, colorectal cancer, pancreatic cancer, or gastric cancer.
[0208] In some embodiments, it is a method of treating triple-negative breast cancer (TNBC), urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, esophageal cancer, head and neck cancer, prostate cancer or endometrial cancer in a subject in need thereof, comprising administering to the subject a polypeptide or polypeptide complex as described herein. In some embodiments, it is a method of treating breast cancer, lung cancer, urothelial cancer, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, head and neck cancer and glioma in a subject in need thereof, comprising administering to the subject a polypeptide or polypeptide complex as described herein.
[0209] Antibody production
[0210] In some embodiments, the polypeptides described herein (e.g., antibodies and binding fragments thereof) are produced using any method known in the art for synthesizing polypeptides (e.g., antibodies), in particular by chemical synthesis or by recombinant expression, and preferably by recombinant expression technology.
[0211] In some cases, antibodies or binding fragments thereof are expressed recombinantly and nucleic acids encoding the antibodies or binding fragments thereof are assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., 1994, BioTechniques 17:242), which involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligation of those oligonucleotides, and subsequent amplification of the ligated oligonucleotides by PCR.
[0212] Alternatively, nucleic acid molecules encoding antibodies are optionally generated from a suitable source (e.g., an antibody cDNA library, or a cDNA library produced by any tissue or cell expressing immunoglobulins) by PCR amplification using synthetic primers that hybridize to the 3' and 5' ends of the sequence or by cloning using oligonucleotide probes specific for a particular gene sequence.
[0213] In some cases, the antibody or its binding partner is optionally produced by immunizing an animal (e.g., a mouse) to produce polyclonal antibodies, or more preferably by producing monoclonal antibodies, e.g., as described in Kohler and Milstein (1975, Nature 256:495-497) or in Kozbor et al. (1983, Immunology Today 4:72) or Cole et al. (1985 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Alternatively, clones encoding at least the Fab portion of the antibody are optionally obtained by screening a Fab expression library (e.g., as described in Huse et al., 1989, Science 246: 1275-1281) for clones that bind to the specific antigen in the Fab fragment or by screening antibody libraries (see, e.g., Clackson et al., 1991, Nature 352: 624; Hane et al., 1997 Proc. Natl. Acad. Sci. USA 94: 4937).
[0214] In some embodiments, a technique for producing "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. 81: 851-855; Neuberger et al., 1984, Nature 312: 604-608; Takeda et al., 1985, Nature 314: 452-454) is used by splicing genes from mouse antibody molecules with appropriate antigen specificity with genes from human antibody molecules with appropriate biological activity. Chimeric antibodies are molecules in which different portions are derived from different animal species, such as those having variable regions derived from mouse monoclonal antibodies and human immunoglobulin constant regions.
[0215] In some embodiments, the techniques described for producing single-chain antibodies (U.S. Pat. No. 4,694,778; Bird, 1988, Science 242: 423-42; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85: 5879-5883; and Ward et al., 1989, Nature 334: 544-54) are adapted to produce single-chain antibodies. The heavy chain and light chain fragments of the Fv region are connected by an amino acid bridge to form a single-chain antibody, producing a single-chain polypeptide. The technique of assembling functional Fv fragments in E. coli (Skerra et al., 1988, Science 242: 1038-1041) is also optionally used.
[0216] In some embodiments, an expression vector comprising the nucleotide sequence of the antibody or the nucleotide sequence of the antibody is transferred to a host cell by conventional techniques (e.g., electroporation, liposome transfection, and calcium phosphate precipitation), and the transfected cells are then cultured by conventional techniques to produce the antibody. In specific embodiments, the expression of the antibody is regulated by a constitutive, inducible, or tissue-specific promoter.
[0217] In some embodiments, a variety of host-expression vector systems are utilized to express the antibodies or binding fragments thereof described herein. Such host-expression systems represent vehicles by which antibody coding sequences are produced and subsequently purified, but also represent cells that express antibodies or binding fragments thereof in situ when transformed or transfected with appropriate nucleotide coding sequences. These include, but are not limited to, microorganisms such as bacteria (e.g., Escherichia coli and Bacillus subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody or binding fragment coding sequences; yeast (e.g., Saccharomyces Pichia) transformed with recombinant yeast expression vectors containing antibody or binding fragment coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody or binding fragment coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody or binding fragment coding sequences; or mammalian cell systems (e.g., COS, CHO, BH, 293, 293T, 3T3 cells) carrying recombinant expression constructs containing promoters derived from mammalian cell genomes (e.g., metallothionein promoters) or promoters derived from mammalian viruses (e.g., adenovirus late promoter; vaccinia virus 7.5K promoter).
[0218] In order to produce recombinant protein for a long time and in high yield, preferably stably expressed. In some cases, the cell line of the antibody of the through engineering stably expressed antibody is optionally used. Instead of using the expression vector containing the viral replication origin, the host cell is transformed with the DNA controlled by the appropriate expression control element (for example, promoter, enhancer, sequence, transcription terminator, polyadenylation site, etc.) and the selectable marker. After introducing foreign DNA, the cell of through engineering is grown in the enrichment medium for 1-2 days, and then transferred to the selective medium. The selectable marker in the recombinant plasmid confers resistance to selection, and allows the cell to stably integrate the plasmid into their chromosome and grow to form a conversion foci (foci), which is cloned and expanded into a cell line. This method can be advantageously used for the cell line of through engineering expression antibody or its binding fragment.
[0219] In some cases, a number of selection systems are used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 192, Proc. Natl. Acad. Sci. USA 48:202), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes for tk cells, hgprt cells, or aprt cells, respectively. In addition, antimetabolite resistance was used as the basis for selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77:357; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Clinical Pharmacy 12:488-505; Wu and Wu, 1991, Biotherapy 13:57-63). 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May 1993, TIBTECH 11(5):155-215); and hygro, which confers resistance to hygromycin (Santerre et al., 1984, Gene 30:147). Methods generally known in the field of recombinant DNA technology that can be used are described in Ausubel et al. (eds., 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY; and Dracopoli et al. (eds.), 1994, Current Protocols in Human Genetics, John Wiley & Sons, NY. Chapters 12 and 13; Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1).
[0220] In some cases, the expression level of the antibody is increased by vector amplification (for review, see Bebbington and Hentschel, the use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3. (Academic Press, New York, 1987)). When the marker in the vector system expressing the antibody is amplifiable, the increase in the inhibitor level present in the host cell culture will increase the copy number of the marker gene. Since the amplified region is related to the nucleotide sequence of the antibody, the production of the antibody will also increase (Crouse et al., 1983, Mol. Cell Biol. 3: 257).
[0221] In some cases, any method known in the art for purifying antibodies is used, for example, by chromatography (e.g., ion exchange; affinity, particularly by affinity for a specific antigen after protein A; and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for purifying proteins.
[0222] Expression vector
[0223] In some embodiments, the vector includes any suitable vector derived from a eukaryotic or prokaryotic source. In some cases, the vector is obtained from bacteria (e.g., Escherichia coli), insects, yeast (e.g., Pichia pastoris), algae or mammalian sources. Exemplary bacterial vectors include pACYC177, pASK75, pBAD vector series, pBADM vector series, pET vector series, pETM vector series, pGEX vector series, pHAT, pHAT2, pMal-c2, pMal-p2, pQE vector series, pRSETA, pRSET B, pRSET C, pTrcHis2 series, pZA31-Luc, pZE21-MCS-1, pFLAG ATS, pFLAG CTS, pFLAG MAC, pFLAG Shift-12c, pTAC-MAT-1, pFLAG CTC or pTAC-MAT-2.
[0224] Exemplary insect vectors include pFastBac1, pFastBac DUAL, pFastBac ET, pFastBac HTa, pFastBac HTb, pFastBac HTc, pFastBac M30a, pFastBact M30b, pFastBac, M30c, pVL1392, pVL1393, pVL1393 M10, pVL1393M11, pVL1393 M12, a FLAG vector such as pPolh-FLAG1 or pPolh-MAT 2, or a MAT vector such as pPolh-MAT1 or pPolh-MAT2.
[0225] In some cases, the yeast vector includes pDEST TM 14 carriers, pDEST TM 15 carriers, pDEST TM 17 carriers, pDEST TM 24 carriers, pYES-DEST52 vector, pBAD-DEST49 Destination vector, pAO815 Pichia vector, pFLD1 Pichia pastoris vector, pGAPZA, B, & C Pichia pastoris vector, pPIC3.5K Pichia vector, pPIC6A, B, & C Pichia vector, pPIC9K Pichia vector, pTEF1 / Zeo, pYES2 yeast vector, pYES2 / CT yeast vector, pYES2 / NT A, B, & C yeast vector, or pYES3 / CT yeast vector.
[0226] Exemplary algal vectors include pChlamy-4 vectors or MCS vectors.
[0227] Examples of mammalian vectors include transient expression vectors or stable expression vectors. Mammalian transient expression vectors may include pRK5, p3xFLAG-CMV 8, pFLAG-Myc-CMV 19, pFLAG-Myc-CMV 23, pFLAG-CMV 2, pFLAG-CMV 6a, b, c, pFLAG-CMV 5.1, pFLAG-CMV 5a, b, c, p3xFLAG-CMV 7.1, pFLAG-CMV 20, p3xFLAG-Myc-CMV 24, pCMV-FLAG-MAT1, pCMV-FLAG-MAT2, pBICEP-CMV 3, or pBICEP-CMV 4. The mammalian stable expression vector may include pFLAG-CMV 3, p3xFLAG-CMV 9, p3xFLAG-CMV 13, pFLAG-Myc-CMV 21, p3xFLAG-Myc-CMV 25, pFLAG-CMV 4, p3xFLAG-CMV 10, p3xFLAG-CMV 14, pFLAG-Myc-CMV 22, p3xFLAG-Myc-CMV 26, pBICEP-CMV 1, or pBICEP-CMV 2.
[0228] In some cases, the cell-free system is a mixture of cytoplasmic and / or nuclear components from cells and is used for in vitro nucleic acid synthesis. In some cases, the cell-free system utilizes prokaryotic cell components or eukaryotic cell components. Sometimes, nucleic acid synthesis is obtained in a cell-free system based on, for example, Drosophila cells, African clawed frog eggs, or HeLa cells. Exemplary cell-free systems include, but are not limited to, E. coli S30 extract system, E. coli T7 S30 system or
[0229] Host cells
[0230] In some embodiments, host cells include any suitable cells, such as cells of natural origin or genetically modified cells. In some cases, host cells are production host cells. In some cases, host cells are eukaryotic cells. In other cases, host cells are prokaryotic cells. In some cases, eukaryotic cells include fungi (e.g., yeast cells), animal cells or plant cells. In some cases, prokaryotic cells are bacterial cells. Examples of bacterial cells include gram-positive bacteria or gram-negative bacteria. Sometimes gram-negative bacteria are anaerobic, rod-shaped or both.
[0231] In some cases, the gram-positive bacteria include Actinobacteria, Firmicutes, or Tenericutes. In some cases, the gram-negative bacteria include Aquificae, Deinococcus-Thermus, Fibrobacteres-Chlorobi / Bacteroidetes (FCB group), Fusobacteria, Gemmatimonadetes, Nitrospirae, Planctomycetes-Verrucomicrobia / Chlamydiae (PVC group), Proteobacteria, Spirochaetes, or Synergistetes. The other bacteria may be Acidobacteria, Chloroflexi, Chrysiogenetes, Cyanobacteria, Deferribacteres, Dictyoglomi, Thermodesulfobacteria or Thermotogae. The bacterial cell may be Escherichia coli, Clostridium botulinum or Coli bacilli.
[0232] Exemplary prokaryotic host cells include, but are not limited to, BL21, Mach1 TM 、DH10B TM 、TOP10、DH5α、DH10Bac TM 、OmniMax TM 、MegaX TM DH12S TM , INV110, TOP10F', INVαF, TOP10 / P3, ccdB Survival, PIR1, PIR2, Stbl2 TM 、Stbl3 TM or Stbl4 TM .
[0233] In some cases, animal cells include cells from vertebrates or from invertebrates. In some cases, animal cells include cells from marine invertebrates, fish, insects, amphibians, reptiles, or mammals. In some cases, fungal cells include yeast cells, such as brewer's yeast, baker's yeast, or wine yeast.
[0234] Fungi include ascomycetes, molds, filamentous fungi, basidiomycetes or zygomycetes such as yeast. In some cases, yeast includes Ascomycetes or Basidiomycota. In some cases, Ascomycetes include Saccharomycotina (true yeast, such as Saccharomyces cerevisiae (baker's yeast)) or Taphrinomycota (Taphrinomycota) (for example, Schizosaccharomycetes (fission yeast)). In some cases, Basidiomycota includes Agaricomycota (Agaricomycotina) (for example, Tremellomycetes) or Pucciniomycotina (Pucciniomycotina) (for example, Microbotryomycetes).
[0235] Exemplary yeasts or filamentous fungi include, e.g., the genera Saccharomyces, Schizosaccharomyces, Candida, Pichia, Hansenula, Kluyveromyces, Zygosaccharomyces, Yarrowia, Trichosporon, Rhodosporidi, Aspergillus, Fusarium, or Trichoderma. Exemplary yeasts or filamentous fungi include, e.g., the following species: Saccharomyces cerevisiae, Schizosaccharomyces pombe, Candida utilis, Candida boidini, Candida albicans, Candida tropicalis, Candida stellatoidea, Candida glabrata, Candida krusei, Candida parapsilosis, Candida guilliermondii, Candida viswanathii, Candida lusitaniae, Rhodotorula mucilaginosa, Pichia metanolica, Pichia angusta, Pichia pastoris, pastoris), Pichia anomala, Hansenula polymorpha, Kluyveromyces lactis, Zygosaccharomyces rouxii, Yarrowialipolytica, Trichosporon pullulans, Rhodosporidium toru-Aspergillus niger, Aspergillus nidulans, Aspergillus avasonii,awamori, Aspergillus oryzae, Trichoderma reesei, Yarrowia lipolytica, Brettanomyces bruxellensis, Candida stellata, Schizosaccharomyces pombe, Torulaspora delbrueckii, Zygosaccharomyces bailii, Cryptococcus neoformans, Cryptococcus gattii, or Saccharomyces boulardii.
[0236] Exemplary yeast host cells include, but are not limited to, Pichia pastoris yeast strains such as GS115, KM71H, SMD1168, SMD1168H, and X-33; and Saccharomyces cerevisiae yeast strains such as INVSc1.
[0237] In some cases, other animal cells include cells obtained from molluscs, arthropods, annelids or sponges. In some cases, other animal cells are mammalian cells, such as from primates, apes, horses, cattle, pigs, dogs, cats or rodents. In some cases, rodents include mice, rats, hamsters, gerbils, hamsters, chinchillas (chinchilla), squirrels or guinea pigs.
[0238] Exemplary mammalian host cells include, but are not limited to, 293A cell line, 293FT cell line, 293F cells, 293H cells, CHO DG44 cells, CHO-S cells, CHO-K1 cells, FUT8 KO CHOK1, Expi293F TM Cells, Flp-In TM T-REx TM 293 cell line, Flp-In TM -293 cell line, Flp-In TM -3T3 cell line, Flp-In TM -BHK cell line, Flp-In TM -CHO cell line, Flp-In TM -CV-1 cell line, Flp-In TM -Jurkat cell line, FreeStyle TM 293-F cells, FreeStyleTM CHO-S cells, GripTite TM 293MSR cell line, GS-CHO cell line, HepaRG TM Cells, T-REx TM Jurkat cell line, Per.C6 cell, T-REx TM -293 cell line, T-REx TM -CHO cell lines and T-REx TM -HeLa cell line.
[0239] In some cases, the mammalian host cell is a stable cell line, or a cell line that has integrated the genetic material of interest into its own genome and has the ability to express the product of the genetic material after many generations of cell division. In some cases, the mammalian host cell is a transient cell line, or a cell line that has not integrated the genetic material of interest into its own genome and does not have the ability to express the product of the genetic material after many generations of cell division.
[0240] Exemplary insect host cells include, but are not limited to, Drosophila S2 cells, Sf9 cells, Sf21 cells, High Five TM Cells and cell.
[0241] In some cases, the plant cell comprises a cell from algae.Exemplary insect cell lines include, but are not limited to, strains from Chlamydomonas reinhardtii 137c or Synechococcuse longatus PPC 7942.
[0242] Products
[0243] In another aspect of the invention, an article containing materials for treating, preventing and / or diagnosing the above-mentioned conditions is provided. The article comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container can be formed of various materials such as glass or plastic. The container holds a composition, which is effective for treating, preventing and / or diagnosing the condition by itself or in combination with another composition, and can have a sterile entrance (for example, the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic injection needle). At least one active agent in the composition is: a bispecific antibody comprising a first antigen binding site that specifically binds to CD3 and a second antigen binding site that specifically binds to TROP2, as defined above.
[0244] The label or package insert indicates that the composition is used to treat the selected condition. In addition, the article of manufacture may include (a) a first container containing a composition, wherein the composition comprises a bispecific antibody of the invention; and (b) a second container containing a composition, wherein the composition comprises an additional cytotoxic agent or other therapeutic agent. The article of manufacture in this embodiment of the invention may also include a package insert indicating that the composition can be used to treat a specific condition.
[0245] Alternatively or additionally, the article of manufacture may further comprise: a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials required from a commercial and user perspective, including other buffers, diluents, filters, needles and syringes.
[0246] Implementation
[0247] Embodiment 1 includes a recombinant antibody or antigen-binding fragment thereof comprising a tumor-associated calcium signal transducer protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 1; wherein CDR2-L comprises the amino acid sequence of SEQ ID NO: 2. NO:2 amino acid sequence; and wherein CDR3-L comprises the amino acid sequence of X1X2HYX3X4X5X6X7; wherein X1 is Q, S, T, D, N, E, H, K, R or A; X2 is Q, S, T, D, N, E, H, K, R or A; X3 is I, G, P, V, L, M, S, T or A; X4 is T, G, S, M, H, N, Q or A; X5 is P, G, V, L, I, M, S, T or A; X6 is L, G, P, V, I, M, S, T or A; and X7 is T, G, S, M, H, N, Q or A; wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:13; wherein CDR2-H comprises the amino acid sequence of SEQ ID NO:14; and wherein CDR3-H comprises AX8X9GX 10 X 11 X 12 X 13 YW 14 X 15 X 16 X 17 wherein X8 is R, S, T, Q, D, E, H, K, N, H, K or A; X9 is G, P, V, L, I, M, S, T or A; X10 is F, Y, W, V, L, I, G, or A; X 11 is G, P, V, L, I, M, S, T, or A; X 12 is S, G, T, M, N, Q, H or A; X 13 is S, G, T, M, N, Q, H or A; X 14 is Y, F, W, V, L, I, G, or A; X 15 is F, Y, W, V, L, I, G, or A; X 16 is D, Q, N, E, S, T, H, K, R, or A; and X 17 is V, G, P, L, I, M, S, T or A; wherein when CDR3-H comprises the amino acid sequence of SEQ ID NO: 15, CDR3-L does not comprise the amino acid sequence of SEQ ID NO: 3.
[0248] Embodiment 2 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 1, wherein X1 is Q, N, D, E or A; X2 is Q, N, D, E or A; X3 is I, V, L or A; X4 is T, S or A; X5 is P, G or A; X6 is L, V, I or A; X7 is T, S or A; X8 is R, K or A; X9 is G, S, T or A; X 10 is F, Y or A; X 11 is G, S, T or A; X 12 is S, G, T or A; X 13 is S, G, T or A; X 14 is Y, W, F or A; X 15 is F, Y, W or A; X 16 is D, E, Q, N, or A; and X 17 It is V, L, I or A.
[0249] Embodiment 3 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 1, wherein X1 is Q; and X6 is L.
[0250] Embodiment 4 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 3, wherein X8 is R; X 10 It is F;X 11 It is G; X 14 It is Y; X 15 is F; and X 16 It is D.
[0251] Embodiment 5 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 1, wherein X1 is Q, S, T, D, N, E or A; X2 is Q, S, T, D, N, E or A; X3 is I, G, P, V, L, M or A; X4 is T, G, S, M, H, N, Q or A; X5 is P, G, V, L, I, M or A; X6 is L, G, P, V, I, M or A; X7 is T, G, S, M, H, N, Q or A; X8 is R, H, K or A; X9 is G, P, V, L, I, M, S, T or A; X 10 is F, Y, W, V, L, I or A; X 11 is G, P, V, L, I, M, S, T, or A; X 12 is S, G, T, M, N, Q or A; X 13 is S, G, T, M, N, Q or A; X 14 is Y, F, W, V, L, I or A; X 15 is F, Y, W, V, L, I or A; X 16 is D, Q, N, E, S, T, or A; and X 17 It is V, G, P, L, I, M or A.
[0252] Embodiment 6 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 5, wherein X1 is Q, N or A; X2 is Q, N or A; X3 is I, V, L or A; X4 is T, S or A; X5 is P, G or A; X6 is L, V, I or A; X7 is T, S or A; X8 is R, K or A; X9 is G, V, S, T or A; X 10 is F, Y or A; X 11 is G, V, S, T or A; X 12 is S, G, T or A; X 13 is S, G, T or A; X 14 is Y, W or A; X 15 is F, Y or A; X 16 is D, E, or A; and X 17 It is V, G, L, I or A.
[0253] Embodiment 7 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 5, wherein X1 is Q; and X6 is L.
[0254] Embodiment 8 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 7, wherein X8 is R; X 10 It is F;X 11 It is G; X 14 It is Y; X 15 is F; and X 16 It is D.
[0255] Embodiment 9 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 1, wherein CDR3-L comprises an amino acid selected from the group consisting of SEQ ID NOs: 3-5 and 8-12.
[0256] Embodiment 10 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 1 or 9, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 8 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15. NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:10 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:11 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:12 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15.
[0257] Embodiment 11 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1 and 9-10, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 5 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 8 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 9 and CDR1-H: SEQ ID NO: 14, CDR2-H: SEQ ID NO: 15. NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:10 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:12 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15.
[0258] Embodiment 12 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 1, wherein CDR3-H comprises amino acids selected from the group consisting of SEQ ID NOs: 16-17, 19-22, and 25-28.
[0259] Embodiment 13 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 1 or 2, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14; CDR3-H: SEQ ID NO: 16; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17. NO:14, CDR3-H: SEQ ID NO:19; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:20; CDR1-L: SEQID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:22; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:25; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:26;CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:27; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:28. ;
[0260] Embodiment 14 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1 and 12-13, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 17; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 21; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 3, and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 21. NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:22; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:28.
[0261] Embodiment 15 includes a recombinant antibody or an antigen-binding fragment thereof comprising a tumor-associated calcium signaling protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the following: CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; CDR1-L: SEQ ID NO: 1, CDR2-L: SEQ ID NO: 2, CDR3-L: SEQ ID NO: 4 NO:5 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:6 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:7 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:8 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:10 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15;CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:11, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:12, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:16; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:17; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:18; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:19; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:20; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2; CDR3-L: SEQ ID NO:3, and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2;CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14; CDR3-H: SEQ ID NO:22; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:23; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:24; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:25; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:26; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:27; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2, CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 28. ;
[0262] Embodiment 16 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-15, wherein the TROP2 binding domain comprises Fab, Fab', (Fab')2 or a single chain variable fragment (scFv).
[0263] Embodiment 17 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-16, wherein the TROP2 binding domain is a Fab.
[0264] Embodiment 18 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-17, wherein the immunoglobulin light chain comprises the variable domain of an immunoglobulin kappa (IgK) or immunoglobulin lambda (IgL) light chain.
[0265] Embodiment 19 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-18, wherein the immunoglobulin heavy chain comprises the variable domain of an IgG1, IgG2, IgG3, or IgG4 heavy chain.
[0266] Embodiment 20 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-19, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO:31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71 or 73.
[0267] Embodiment 21 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-20, wherein the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO:32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72 or 74.
[0268] Embodiment 22 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:31, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:32.
[0269] Embodiment 23 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:33, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:34.
[0270] Embodiment 24 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:35, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:36.
[0271] Embodiment 25 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:37, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:38.
[0272] Embodiment 26 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:39, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:40.
[0273] Embodiment 27 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:41, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:42.
[0274] Embodiment 28 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:43, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:44.
[0275] Embodiment 29 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:45, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:46.
[0276] Embodiment 30 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:47, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:48.
[0277] Embodiment 31 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:49, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:50.
[0278] Embodiment 32 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:51, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:52.
[0279] Embodiment 33 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:53, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:54.
[0280] Embodiment 34 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:55, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:56.
[0281] Embodiment 35 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:57, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:58.
[0282] Embodiment 36 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:59, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:60.
[0283] Embodiment 37 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:61, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:62.
[0284] Embodiment 38 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:63, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:64.
[0285] Embodiment 39 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:65, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:66.
[0286] Embodiment 40 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:67, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:68.
[0287] Embodiment 41 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:69, and the immunoglobulin heavy chain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:70.
[0288] Embodiment 42 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:71, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:72.
[0289] Embodiment 43 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:73, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:74.
[0290] Embodiment 44 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the TROP2 binding domain has weaker binding to TROP2 than a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO:29 and an immunoglobulin heavy chain according to SEQ ID NO:30 as measured by ELISA under substantially similar assay conditions.
[0291] Embodiment 45 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the TROP2 binding domain has an increased EC for TROP2 compared to a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO: 29 and an immunoglobulin heavy chain according to SEQ ID NO: 30 as measured by ELISA under substantially similar assay conditions. 50 .
[0292] Embodiment 46 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-2 and 15-21, wherein the TROP2 binding domain has a faster dissociation rate (greater k) for TROP2 binding than a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO: 29 and an immunoglobulin heavy chain according to SEQ ID NO: 30 as measured under substantially similar kinetic assay conditions. diss ).
[0293] Embodiment 47 includes the recombinant antibody or antigen binding fragment thereof of any one of embodiments 1-46, wherein the recombinant antibody or antigen binding fragment further comprises a CD3 binding domain.
[0294] Embodiment 48 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 47, wherein the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO:75, wherein CDR2-L comprises the amino acid sequence of SEQ ID NO:76, wherein CDR3-L comprises the amino acid sequence of SEQ ID NO:77, wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:78, wherein CDR2-H comprises the amino acid sequence of SEQ ID NO:79, and wherein CDR3-H comprises the amino acid sequence of SEQ ID NO:80.
[0295] Embodiment 49 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 47, wherein the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 75; wherein CDR2-L comprises the amino acid sequence of SEQ ID NO: 76. NO:76 amino acid sequence; wherein CDR3-L comprises the amino acid sequence of Z1-Z2-W-Z3-Z4-Z5-Z6-W-Z7-Z8; wherein Z1 is V, G, P, L, I, M, S, T or A; Z2 is L, G, P, V, I, M, S, T or A; Z3 is Y, F, W, V, L, I, G or A; Z4 is S, G, T, M, N, Q, H or A; Z5 is N, Q, S, T, D, E, H, K, R or A; Z6 is R, S, T, Q, D, E, H, K, N or A; Z7 is V, G, P, L, I, M, S, T or A; and Z8 is F, Y, W, V, L, I, G or A; wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:78; wherein CDR2-H comprises SEQ ID NO:79 amino acid sequence; wherein CDR3-H comprises Z9-Z 10 -Z 11 -Z 12 -NZ 13 -Z 14 -Z 15 -Z 16 -Z 17 -Z 18 -Z 19 -YZ 20 -AZ 21 wherein Z9 is V, G, P, L, I, M, S, T or A; 10 is R, S, T, Q, D, E, H, K, N, or A; Z 11 is H, R, K, G, T, S, N, Q or A; Z 12 is G, P, V, L, I, M, S, T, or A; Z 13 is F, Y, W, V, L, I, G or A; Z 14 is G, P, V, L, I, M, S, T, or A; Z 15 is N, Q, S, T, D, E, H, K, R or A; Z 16 is S, G, T, M, N, Q, H or A; Z 17 is Y, F, W, V, L, I, G or A; Z 18 is I, G, P, V, L, M, S, T, or A; Z 19is S, G, T, M, N, Q, H or A; Z 20 is W, F, Y, V, L, I, G, or A; and Z 21 It is Y, F, W, V, L, I, G or A.
[0296] Embodiment 50 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49, wherein: Z1 is V, G, L, I or A; Z2 is L, V, I or A; Z3 is Y, W, F or A; Z4 is S, G, T or A; Z5 is N, Q, D, E or A; Z6 is R, K or A; Z7 is V, G, L, I or A; Z8 is F, Y, W or A; Z9 is V, G, L, I or A; 10 is R, K or A; Z 12 is G, S, T or A; Z 13 is F, Y, W or A; Z 14 is G, S, T or A; Z 15 is N, Q, D, E or A; Z 16 is S, G, T or A; Z 17 is Y, W, F or A; Z 18 is I, V, L or A; Z 19 is S, G, T or A; Z 20 is W, Y, F or A; and Z 21 It is Y, W, F or A.
[0297] Embodiment 51 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 50, wherein: Z8 is F.
[0298] Embodiment 52 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 49-51, wherein: Z 10 It is R; Z 11 It is H; Z 13 It is F; Z 18 It is I; Z 19 is S; and Z 20 It's W.
[0299] Embodiment 53 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49, wherein CDR3-L comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 77, 105-106, 108-111 and 113-114.
[0300] Embodiment 54 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 105, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 106, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80;and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:114 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80.;
[0301] Embodiment 55 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 105, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 106, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80.
[0302] Embodiment 56 includes the antibody or antigen-binding fragment thereof of embodiment 49, wherein CDR3-H comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 80, 116-119, 121-127 and 129-130.
[0303] Embodiment 57 comprises an immunoglobulin light chain and an immunoglobulin heavy chain comprising a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 116; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 117; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 117. NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:118; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:121; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:125; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:126; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:127; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:129; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:130.;
[0304] Embodiment 58 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 116; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 119; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 77, and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 119. NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:125; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:130.
[0305] Embodiment 59 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 47, wherein the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 105 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; CDR1-L: SEQ ID NO: 75, CDR2-L: SEQ ID NO: 76, CDR3-L: SEQ ID NO: 106 and CDR1-H: SEQ ID NO: 81. NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:107 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:108 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L:SEQ ID NO:109 and CDR1-H:SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:111, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:112, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:114, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:116; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:117; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:118; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77, and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:120; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:121; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:125; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:126; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:127;CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:128; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:129; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:130. ;
[0306] Embodiment 60 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 47-59, wherein the immunoglobulin light chain of the CD3 binding domain comprises the variable domain of an immunoglobulin kappa (IgK) or immunoglobulin lambda (IgL) light chain.
[0307] Embodiment 61 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 47-60, wherein the immunoglobulin heavy chain of the CD3 binding domain comprises the variable domain of an IgG1, IgG2, IgG3 or IgG4 heavy chain.
[0308] Embodiment 62 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 47-48, wherein the immunoglobulin light chain of the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:81.
[0309] Embodiment 63 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 47-48, wherein the immunoglobulin heavy chain of the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:82.
[0310] Embodiment 64 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 47-48, wherein the immunoglobulin light chain of the CD3 binding domain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:81, and the immunoglobulin heavy chain of the CD3 binding domain comprises an amino acid sequence at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:82.
[0311] Embodiment 65 includes the recombinant antibody or antigen binding fragment thereof of any one of embodiments 47-64, wherein the CD3 binding domain comprises Fab, Fab', (Fab')2 or a single chain variable fragment (scFv).
[0312] Embodiment 66 includes the recombinant antibody or antigen binding fragment thereof of embodiment 65, wherein the CD3 binding domain is a scFv.
[0313] Embodiment 67 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 47-48, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:99.
[0314] Embodiment 68 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:131.
[0315] Embodiment 69 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:132.
[0316] Embodiment 70 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:133.
[0317] Embodiment 71 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:134.
[0318] Embodiment 72 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:135.
[0319] Embodiment 73 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:136.
[0320] Embodiment 74 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:137.
[0321] Embodiment 75 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:138.
[0322] Embodiment 76 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:139.
[0323] Embodiment 77 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:140.
[0324] Embodiment 78 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:141.
[0325] Embodiment 79 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:142.
[0326] Embodiment 80 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:143.
[0327] Embodiment 81 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:144.
[0328] Embodiment 82 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:145.
[0329] Embodiment 83 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:146.
[0330] Embodiment 84 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:147.
[0331] Embodiment 85 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:148.
[0332] Embodiment 86 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:149.
[0333] Embodiment 87 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:150.
[0334] Embodiment 88 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:151.
[0335] Embodiment 89 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:152.
[0336] Embodiment 90 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:153.
[0337] Embodiment 91 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:154.
[0338] Embodiment 92 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 49 or 59, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:155.
[0339] Embodiment 93 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 48-92, wherein the N-terminus of the immunoglobulin heavy chain of the TROP2 binding domain is bound to the C-terminus of the immunoglobulin light chain of the CD3 binding domain.
[0340] Embodiment 94 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 48-92, wherein the C-terminus of the immunoglobulin heavy chain of the TROP2 binding domain is bound to the N-terminus of the immunoglobulin light chain of the CD3 binding domain.
[0341] Embodiment 95 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 48-92, wherein the N-terminus of the immunoglobulin heavy chain of the TROP2 binding domain is bound to the C-terminus of the immunoglobulin heavy chain of the CD3 binding domain.
[0342] Embodiment 96 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 48-92, wherein the C-terminus of the immunoglobulin heavy chain of the TROP2 binding domain is bound to the N-terminus of the immunoglobulin heavy chain of the CD3 binding domain.
[0343] Embodiment 97 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 48-92, wherein the N-terminus of the immunoglobulin light chain of the TROP2 binding domain is bound to the C-terminus of the immunoglobulin light chain of the CD3 binding domain.
[0344] Embodiment 98 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 48-92, wherein the C-terminus of the immunoglobulin light chain of the TROP2 binding domain is bound to the N-terminus of the immunoglobulin light chain of the CD3 binding domain.
[0345] Embodiment 99 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 48-92, wherein the N-terminus of the immunoglobulin light chain of the TROP2 binding domain is bound to the C-terminus of the immunoglobulin heavy chain of the CD3 binding domain.
[0346] Embodiment 100 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 48-92, wherein the C-terminus of the immunoglobulin light chain of the TROP2 binding domain is bound to the N-terminus of the immunoglobulin heavy chain of the CD3 binding domain.
[0347] Embodiment 101 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 48-100, wherein the CD3 binding domain is a scFv and the TROP2 binding domain is a Fab or Fab'.
[0348] Embodiment 102 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 101, wherein the scFv is bound to the immunoglobulin heavy chain of Fab or Fab'.
[0349] Embodiment 103 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 101, wherein the scFv is bound to the immunoglobulin light chain of Fab or Fab'.
[0350] Embodiment 104 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 101, wherein the immunoglobulin light chain of the scFv is bound to the immunoglobulin heavy chain of the Fab or Fab'.
[0351] Embodiment 105 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 101, wherein the immunoglobulin light chain of the scFv is combined with the immunoglobulin light chain of the Fab or Fab'.
[0352] Embodiment 106 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 101, wherein the immunoglobulin heavy chain of the scFv is combined with the immunoglobulin heavy chain of the Fab or Fab'.
[0353] Embodiment 107 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 101, wherein the immunoglobulin heavy chain of the scFv is bound to the immunoglobulin light chain of the Fab or Fab'.
[0354] Embodiment 108 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15 and 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:87 and SEQ ID NO:88.
[0355] Embodiment 109 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15 and 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:89 and SEQ ID NO:90.
[0356] Embodiment 110 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15 and 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:91 and SEQ ID NO:92.
[0357] Embodiment 111 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15 and 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:93 and SEQ ID NO:94.
[0358] Embodiment 112 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15 and 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:95 and SEQ ID NO:96.
[0359] Embodiment 113 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15 and 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:97 and SEQ ID NO:98.
[0360] Embodiment 114 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15, 47, 49 and 59, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:158 and SEQ ID NO:188.
[0361] Embodiment 115 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15, 47, 49 and 59, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:158 and SEQ ID NO:189.
[0362] Embodiment 116 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15, 47, 49 and 59, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:158 and SEQ ID NO:190.
[0363] Embodiment 117 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15, 47, 49 and 59, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:158 and SEQ ID NO:194.
[0364] Embodiment 118 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15, 47, 49 and 59, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:158 and SEQ ID NO:195.
[0365] Embodiment 119 includes the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1, 15, 47, 49 and 59, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:158 and SEQ ID NO:196.
[0366] Embodiment 120 includes the recombinant antibody or antigen-binding fragment thereof of embodiment 47, wherein the recombinant antibody or antigen-binding fragment thereof has weaker cytotoxic activity than a recombinant antibody or antigen-binding fragment thereof comprising an immunoglobulin light chain according to SEQ ID NO: 83 or 85 and an immunoglobulin heavy chain according to SEQ ID NO: 84 or 86 as measured in an in vitro tumor cell killing assay under substantially similar assay conditions.
[0367] Embodiment 121 includes a pharmaceutical composition comprising: (i) the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-120; and (ii) a pharmaceutically acceptable excipient.
[0368] Embodiment 122 includes an isolated recombinant nucleic acid molecule encoding a polypeptide of the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-120.
[0369] Embodiment 123 includes a method of treating cancer in a subject in need thereof, comprising administering to the subject the recombinant antibody or antigen-binding fragment thereof of any one of embodiments 1-120.
[0370] Embodiment 124 includes the method of embodiment 123, wherein the cancer comprises breast cancer, lung cancer, urothelial cancer, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, head and neck cancer, or glioma.
[0371] Embodiment 125 includes the method of embodiment 124, wherein the breast cancer comprises triple negative breast cancer.
[0372] Embodiment 126 includes the method of embodiment 124, wherein the lung cancer comprises non-small cell lung cancer.
[0373] Example
[0374] Example 1: Alanine scanning of CDR3 of the TROP2 binding domain
[0375] Alanine scanning is carried out to TROP2 binding domain (TBD), to establish the sequence activity relationship (SAR) that CDR3 is relevant.Alanine scanning is completed by mutating each individual residue in CDR3 light chain (LC) region and CDR3 heavy chain (HC) region of anti-TROP2 Fab starting sequence into alanine.The amino acid sequence of the TBD construct of non-mutation (or " wild type ") and mutation is shown in Table 3.TBD-1 is " wild type " or starting sequence anti-TROP2 Fab.TBD-2 to TBD-10 are TBDs with single alanine mutation in CDR3 LC region, and TBD-11 to TBD-23 are TBDs with single alanine mutation in CDR3 HC region.
[0376] Example 2: Binding of TBD to TROP2
[0377] Kinetic binding to TROP2 via BLI
[0378] The ability of the wild-type TBD and alanine-mutated TBD of Example 1 to bind TROP2 was evaluated. Kinetic binding was measured using biolayer interferometry (BLI). Briefly, biotinylated human TROP2 was loaded onto streptavidin-coated On a SAX biosensor, the TBD was quenched in biocytin and baselined in buffer. TBD diluted in buffer then associated with the antigen loaded biosensor. The sensor was then transferred to buffer where the TBD construct then dissociated from the sensor. The association and dissociation rates were calculated using The instrument measures in real time. Example sensorgrams of non-mutant (TBD-1) and CDR3 LC alanine scanning mutants (TBD-2 to TBD-10) are shown in Figure 1A-1J Example sensorgrams of CDR3HC alanine scanning mutants (TBD-11 to TBD-23) are shown in Figure 2A-2M . Exemplary experimental conditions and steps for kinetic binding measurements are shown in Table 9. For both kinetic and equilibrium binding studies, the extracellular domain (ECD) of TROP2 was used (Table 10; SEQ ID NO: 100). The amino acid sequence of the extracellular domain of cynomolgus monkey TROP2 (SEQ ID NO: 101) and the full-length amino acid sequences of human and cynomolgus monkey TROP2 (SEQ ID NO: 102 and SEQ ID NO: 103) are also provided in Table 10.
[0379] Table 9.
[0380]
[0381] Table 10. Human and cynomolgus monkey TROP2 sequences.
[0382]
[0383] Equilibrium binding to TROP2 by ELISA
[0384] The ability of wild-type TBD and alanine-mutated TBD to bind TROP2 in Example 1 was also evaluated using a standard enzyme-linked immunosorbent assay (ELISA) design. Briefly, biotinylated TROP2 was captured on a neutravidin-coated plate. TROP2 Fab construct (TBD) diluted in buffer was then added to the antigen-coated plate. Binding was detected using a standard horseradish peroxidase secondary antibody. The TBD concentration required to achieve 50% maximum signal (EC 50 Binding curves of TBD CDR3 LC and CDR3 HC alanine scanning mutants (TBD-2 to TBD-12) relative to wild-type TBD (TBD-1) and calculated EC 50 Together Figure 3 Binding curves of CDR3 HC alanine scanning mutants (TBD-13 to TBD-23) relative to wild-type TBD (TBD-1) and calculated EC 50 Together Figure 4 Shown in.
[0385] Sequence-activity relationship
[0386] Data summarizing the TROP2 binding parameters obtained from the above kinetic and equilibrium binding studies are provided in Table 11 (CDR3 LC alanine mutant constructs) and Tables 12-13 (CDR3 HC alanine mutant constructs). These tables also indicate each alanine mutation in the CDR3 LC and CDR3 HC regions as tolerated (T), moderately tolerated (MT), or intolerant (NT). Alanine mutations that result in significantly reduced binding relative to the non-mutated TROP2 Fab (TBD-1) are characterized as NT, and those residues are considered to be key residues for TROP2 binding. Alanine mutations that show comparable binding parameters to the non-mutated TROP2 Fab are characterized as T, and those residues are considered to be not critical for TROP2 binding. Alanine mutations that result in slightly reduced binding relative to the non-mutated TROP2 Fab are characterized as MT.
[0387] As can be seen from Table 11, H91A and Y92A mutations in the CDR3 LC region are intolerant and greatly weaken the binding interaction with TROP2. The L96A mutation also disrupts the TROP2 binding interaction. The Q89A mutation is moderately tolerant, while the remaining alanine mutations in the CDR3 LC region are tolerant. The data indicate that H91A and Y92A in the CDR3 LC region are critical for binding to TROP2.
[0388] For alanine mutations in the CDR3 HC region, G100A, Y105A, and W106A mutations were intolerant and substantially disrupted the binding interaction with TROP2, indicating that these residues are critical for binding. F101A and G102A mutations also significantly disrupted binding, indicating that these residues are also important for the binding interaction with the TROP2 antigen. Table 11. TROP2 binding and SAR data for TROP2 Fab CDR3 LC alanine scanning mutants
[0389]
[0390] Table 12. TROP2 binding and SAR data of TROP2 Fab CDR3 HC alanine scanning mutants
[0391]
[0392] Table 13. TROP2 binding and SAR data of TROP2 Fab CDR3 HC alanine scanning mutants
[0393]
[0394] Example 3: Alanine mutation of T cell engager (TCE) sequence
[0395] In the TCE sequence consisting of the TROP2 binding domain connected to the CD3ε binding domain, the selected alanine mutation in the CDR3 HC region of the TROP2 binding domain is carried out. In these sequences, the CD3ε binding domain is an anti-CD3ε single-chain variable fragment (scFv). The amino acid sequence of the TCE construct of non-mutation and the TCE construct of mutation is provided in Table 7. TCE-1 and TCE-2 are the non-mutation constructs that the CD3 binding domain is connected to the TROP2 binding domain HC and the TROP2 binding domain LC respectively. TCE-3 to TCE-5 include the single alanine mutation in the CDR3 HC region of the TROP2 binding domain, and have the CD3 binding domain connected to the TROP2 binding domain LC. Specifically, TCE-3 includes the R98A mutation, and TCE-4 includes the F108A mutation, and TCE-5 includes the D109A mutation. TCE-6 to TCE-8 include a single alanine mutation in the CDR3 HC region of the TROP2 binding domain and have a CD3 binding domain connected to the TROP2 binding domain HC. TCE-6 includes an R98A mutation, TCE-7 includes an F108A mutation, and TCE-8 includes a D109A mutation.
[0396] Surprisingly, the applicant has found that treatment of non-human primates with certain TCE constructs having a single alanine mutation in the CD3 binding domain results in reduced levels of cytokine release compared to treatment with a T cell adapter (TCE) construct having a wild-type CD3 binding domain. That is, with respect to cytokine induction levels in non-human primates, the level is lower in animals that have been administered a maximum tolerated dose of CD3 mutant TCEs compared to animals that have been administered a maximum tolerated dose of wild-type CD3 TCEs. These results illustrate the side effects (e.g., cytokine release syndrome) associated with cytokine release that are alleviated after treatment with certain alanine-mutated constructs. In addition, relative to a more potent wild-type construct, a more potent alanine-mutated TCE construct can achieve a wider therapeutic window between the active dose level and the toxic dose level. This can in turn provide advantages for standard dosing regimens, in which population-based pharmacokinetics variability can be the difference between efficacy and toxicity. For example, when there is a wider drug exposure window between the maximum tolerated dose and the lethal dose, it is less difficult to control drug exposure. The difference in exposure between the maximum tolerated dose and the lethal dose in non-human primates was greater for TCE constructs with reduced CD3 binding affinity and weaker in vitro cytotoxic potency. Further, the less potent alanine-mutated constructs may also have benefits in assays associated with pharmacokinetic monitoring when the detection limit of the assay is above the drug exposure level, compared to more potent molecules that may be difficult to monitor at active doses. Thus, the less potent alanine-mutated constructs disclosed herein may be more easily monitored clinically and advanced in clinical settings.
[0397] Example 4: Binding of TROP-2TCE to TROP2 and CD3
[0398] Kinetic binding to TROP2 via BLI
[0399] The ability of the non-mutated TCE and alanine-mutated TCE of Example 3 to bind TROP2 was evaluated. The binding kinetics were measured using BLI as described above in Example 2. Example sensorgrams of the non-mutated construct TCE-2 and the mutated constructs TCE-3 to TCE-5 are shown in Figure 5A-5D Example sensorgrams of the non-mutated construct TCE-1 and the mutated constructs TCE-6 to TCE-8 are shown in Figure 6A-6D Exemplary experimental conditions and procedures for kinetic binding measurements are shown in Table 14.
[0400] Table 14.
[0401]
[0402]
[0403] Equilibrium binding to TROP2 and CD3 by ELISA
[0404] The ability of the non-mutated TCE and alanine-mutated TCE in Example 3 to bind TROP2 and CD3ε was also evaluated using an ELISA setup. ELISA binding measurements were performed as described in Example 2 using immobilized TROP2 or immobilized CD3ε. Binding curves and EC values for TROP2 and CD3ε binding of the non-mutated constructs TCE-1 and TCE-2 50 exist Figure 7-Figure 8 Binding curves and EC values of mutant constructs TCE-3 to TCE-8 for TROP2 and CD3ε binding are shown in 50 exist Figure 9-12 As shown in Figure 2, all mutations in the CDR3 HC region of TBD resulted in an increase in EC for TROP2 relative to the non-mutated construct. 50 Increase (decreased binding). In contrast, mutations to the CDR3 HC region had little or negligible effect on CD3ε binding relative to the non-mutated construct.
[0405] Example 5: Tumor cell killing by TCE
[0406] The TCE of Example 3 was evaluated in a functional in vitro tumor cell killing assay using TROP2 positive tumor cell lines HCT116, MDAMB231 and NCI-H292. Tumor cell killing was measured using the xCelligence real-time cell analyzer from Agilent, which relies on sensor impedance measurements (cell index) that increase as tumor cells adhere, spread and amplify on the sensor surface. Similarly, as tumor cells are killed, impedance decreases. 10,000 tumor cells were added to each well and allowed to adhere overnight. The next day, TCE titrated in a culture medium supplemented with human serum was added to the wells together with 30,000 CD8+T cells. Cell index measurements were performed every 10 minutes for another 72 hours. The cell index was then multiplied by the number of hours (tumor cell growth kinetics) relative to the TCE concentration, where the concentration required to reduce tumor growth by 50% (EC 50 ). The data graph of tumor cell viability versus TCE concentration is shown in Figures 13A-13F (HCT116 cells), Figure 14A-14F (MDAMB231 cells) and Figure 15A-15E (NCI-H292 cells) are shown. ECs that kill tumor cells of different tumor cell types 50 Provided in Table 15. Cells used for cytotoxicity studies expressed full-length TROP2 antigen (see Table 10).
[0407] Table 15. TCE cytotoxicity EC 50
[0408] TCE HCT116 (pM) MDAMB231(pM) H292(pM) TCE-1 28.6 12.0 1.3 TCE-2 1.6 1.2 - TCE-3 22.0 7.7 0.4 TCE-4 18.3 6.3 0.4 TCE-5 5.8 2.6 0.2 TCE-6 142.5 77.2 6.3 TCE-7 205.8 47 8 5.6 TCE-8 83.0 26.0 4.0
[0409] Example 6: Alanine scanning in TROP2 TCE constructs
[0410] Alanine scanning is performed on the light chain and heavy chain of the anti-CD3 scFv CDR3 of the TROP2 T cell adapter (TCE) construct to establish the sequence activity relationship (SAR) related to anti-CD3 CDR3. Alanine scanning is completed by mutating each individual residue in the CDR3 light chain (LC) region and the CDR3 heavy chain (HC) region of the anti-CD3 scFv starting sequence into alanine. The amino acid sequences of the TCE constructs of non-mutation (or "wild type") and mutation are provided in Table 8. TCE-9 has "wild type" or non-mutation anti-CD3 CDR3 sequences. TCE-10 to TCE-24 have single alanine mutations in anti-CD3 CDR3 heavy chains, and TCE-25 to TCE-34 have single alanine mutations in anti-CD3 CDR3 light chains. TCE-38 to TCE-40 and TCE-44 to TCE-46 included alanine mutations in both the anti-CD3 CDR3 and anti-TROP2 CDR3 heavy chains (double mutants).
[0411] Example 7: Binding of TROP2 TCE to CD3ε and TROP2
[0412] Equilibrium binding to CD3ε and TROP2 by ELISA
[0413] The ability of wild-type TCE and alanine-mutated TCE in Example 6 to bind CD3ε and TROP2 was evaluated using a standard enzyme-linked immunosorbent assay (ELISA) design. Briefly, biotinylated CD3ε or biotinylated TROP2 was captured on a neutravidin-coated plate. TCE constructs diluted in buffer were then added to the antigen-coated plate. Binding was detected using a standard horseradish peroxidase secondary antibody. The TCE concentration required to achieve 50% maximal signal (EC 50 ).
[0414] Binding curves of TCE-9 to TCE-19 binding to human CD3ε and calculated EC 50 Together Fig.16 The binding curves of TCE-9 and TCE-20 to TCE-29 for binding to human CD3ε and the calculated EC 50 Together Fig.17 The binding curves and EC values of TCE-9 and TCE-30 to TCE-36 for binding to human CD3ε are shown in 50 exist Fig.18 Shown in. Fig.19 The binding curves and binding EC of TCE-37 to TCE-42 binding to CD3ε are shown. 50 . Figure 20A-20B Human CD3 ( Fig. 20A ) and cynomolgus monkey CD3 ( Fig. 20B ) Binding curves and binding EC 50 .
[0415] Binding curves and EC of TROP2 binding of TCE-37, TCE-43, TCE-38, TCE-39 and TCE-40 as measured by ELISA 50 exist Fig.21 Binding curves and EC for CD3 binding of TCE-37, TCE-43, TCE-38, TCE-39 and TCE-40 as measured by ELISA 50 exist Fig. 22 Binding curves and EC values for TROP2 binding of TCE-42, TCE-45, TCE-46, and TCE-44 as measured by ELISA 50 exist Fig.23 Binding curves and EC for CD3 binding of TCE-42, TCE-45, TCE-46 and TCE-44 as measured by ELISA 50 exist Fig.24 Shown in.
[0416] Kinetic binding of CD3ε and TROP2 via BLI
[0417] The ability of wild-type (non-mutated) TCE and alanine-mutated TCE to bind CD3ε or TROP2 was assessed via kinetic binding measurements using biolayer interferometry (BLI). Briefly, biotinylated CD3ε or TROP2 was loaded onto streptavidin-coated On a SAX biosensor, the cells were quenched in biocytin and baselined in buffer. TCE diluted in buffer then associated with the antigen loaded biosensor. The sensor was then transferred to buffer where TCE then dissociated from the sensor. The association and dissociation rates were calculated using Instrument real-time measurements. Exemplary experimental conditions and procedures for measurements of kinetic binding to CD3ε are shown in Table 16.
[0418] Table 16.
[0419]
[0420] Example sensorgrams of TCE-10 to TCE-24 (anti-CD3 CDR3 heavy chain mutants) are shown in Figure 25A-Figure 25O Example sensorgrams of TCE-25 to TCE-36 (including anti-CD3 CDR3 light chain mutants) and TCE-9 are shown in Figure 26A-Figure 26N The binding affinity (K) of TCE-9 to TCE-36 calculated from BLI measurements is shown in D ), association rate (k on ) and dissociation rate (k dis ) are provided in Table 17.
[0421] Table 17.
[0422]
[0423]
[0424] Figure 27A-Figure 27D The experimental conditions and steps of Table 18 are shown for TCE-11 ( Fig.27A , anti-CD3 R100A mutant), TCE-12 ( Fig.27B , anti-CD3 H101A mutant), TCE-15 ( Fig.27C , anti-CD3 F104A mutant) and TCE-34 ( Fig.27D Example BLI sensorgrams of TCE-11, TCE-12, TCE-15, and TCE-34 binding to CD3ε. D and k on and k dis The rates are provided in Table 19.
[0425] Table 18.
[0426]
[0427] Table 19.
[0428]
[0429] Figure 28A-28B The wild-type construct TCE-36 ( Fig.28A ) and TCE-9( Fig.28B ) Example BLI sensorgrams of CD3ε binding of TCE-36 and TCE-9. Calculated K for TCE-36 and TCE-9 binding to CD3ε D and k on and k dis The rates are provided in Table 20.
[0430] Table 20.
[0431]
[0432] Example sensorgrams of TCE-37 (wild-type anti-CD3, anti-TROP2F108A) binding to TROP2 and CD3ε and calculated K D , k on and k dis exist Figure 29A-29B As shown in. Figure 29A-29B Exemplary experimental conditions and steps for the measurement of are provided in Table 21.
[0433] Table 21.
[0434]
[0435] Figure 30A-Figure 30B Exemplary sensorgrams of double mutant TCE-38 (anti-CD3 H101A, anti-TROP2 F108A) and double mutant TCE-39 (anti-CD3 F104A, anti-TROP2 F108A) binding to TROP2 using the experimental conditions and procedures of Table 22 are shown. Calculated K values of TCE-38 and TCE-39 binding to TROP2 D and k on and k dis The rates are provided in Table 23.
[0436] Table 22.
[0437]
[0438] Table 23.
[0439] Construct description Sample loading ID <![CDATA[K D (M)]]> <![CDATA[k on (1 / M·s)]]> <![CDATA[k dis (1 / s)]]> TCE-38 TROP2-bio[10nM] 1.56E-09 3.04E+05 4.75E-04 TCE-39 TROP2-bio[10nM] 1.21E-09 3.42E+05 4.14E-04
[0440] Figure 31A-Figure 31B Exemplary sensorgrams of double mutant TCE-38 (anti-CD3 H101A, anti-TROP2 F108A) and double mutant TCE-39 (anti-CD3 F104A, anti-TROP2 F108A) binding to CD3ε are shown using the experimental conditions and procedures of Table 22. Calculated K values of TCE-38 and TCE-39 binding to CD3ε D and k on and k dis The rates are provided in Table 24.
[0441] Table 24.
[0442] Construct description Sample loading ID <![CDATA[K D (M)]]> <![CDATA[k on (1 / M·s)]]> <![CDATA[k dis (1 / s)]]> TCE-38 CD3e-bio[30nM] 5.43E-09 2.04E+05 1.11E-03 TCE-39 CD3e-bio[30nM] 1.40E-08 2.47E+05 3.46E-03
[0443] Example sensorgrams of double mutant TCE-40 (anti-CD3 F240A, anti-TROP2 F108A) binding to TROP2 and CD3ε are shown in Figure 32A-32B The experimental conditions and procedures used for the measurements are provided in Table 25. The calculated K values of TCE-40 binding to TROP2 and CD3ε D and k on and k dis The rates are provided in Table 26.
[0444] Table 25.
[0445]
[0446] Table 26.
[0447] Construct description Sample loading ID <![CDATA[K D (M)]]> <![CDATA[k on (1 / M·s)]]> <![CDATA[k dis (1 / s)]]> TCE-40 TROP2-bio [10nM] 2.92E-09 1.62E+05 4.73E-04 TCE-40 CD3e-bio[30nM] 9.12E-09 2.90E+05 2.64E-03
[0448] Exemplary sensorgrams of TCE-41 (anti-TROP2 F108A mutant) and TCE-42 (anti-TROP2 F108A mutant) binding to CD3ε are shown in Figure 33A-Figure 33B As shown in. Figure 33A-Figure 33B Exemplary experimental conditions and procedures for the measurement of are provided in Table 27, and the calculated K values of TCE-41 and TCE-42 binding to CD3ε are given in Table 27. D and k on and k dis The rates are provided in Table 28.
[0449] Table 27.
[0450]
[0451] Table 28.
[0452] Construct description Sample loading ID <![CDATA[K D (M)]]> <![CDATA[k on (1 / M·s)]]> <![CDATA[k dis (1 / s) <!-- 92 -->]]> TCE-41 Biotinylated CD3e 4.67E-10 8.85E+05 4.14E-04 TCE-42 Biotinylated CD3e 1.62E-09 6.59E+05 1.07E-03
[0453] Exemplary sensorgrams of TCE-41 (anti-TROP2 F108A mutant) and TCE-42 (anti-TROP2 F108A mutant) binding to TROP2 are shown in Figure 34A-Figure 34B As shown in. Figure 34A-Figure 34B Exemplary experimental conditions and procedures for the measurement of are provided in Table 29, and the calculated K values of TCE-41 and TCE-42 binding to TROP2 are given in Table 29. D and k on and k dis The rates are provided in Table 30.
[0454] Table 29.
[0455]
[0456] Table 30.
[0457] Construct description Sample loading ID <![CDATA[K D (M)]]> <![CDATA[k on (1 / M·s)]]> <![CDATA[k dis (1 / s)]]> TCE-41 Biotinylated TROP2 1.22E-09 4.74E+05 5.80E-04 TCE-42 Biotinylated TROP2 8.81E-10 4.76E+05 4.19E-04
[0458] Exemplary sensorgrams of TCE-9 (wild-type anti-CD3, wild-type anti-TROP2), TCE-37 (anti-TROP2 F108A mutant), and TCE-43 (anti-TROP2 D109A mutant) binding to TROP2 are shown in Figure 35A-Figure 35C As shown in. Figure 35A-Figure 35C Exemplary experimental conditions and procedures for the measurement of are provided in Table 31, and the calculated K D and k on and k dis The rates are provided in Table 32.
[0459] Table 31.
[0460]
[0461] Table 32.
[0462]
[0463] Example 8: Sequence Activity Relationship
[0464] The data summarizing the CD3ε binding parameters obtained from the above equilibrium and kinetic binding studies are provided in Table 33 (constructs of anti-CD3 CDR3LC alanine mutations) and Tables 34-35 (constructs of anti-CD3CDR3HC alanine mutations). These tables also classify each alanine mutation in the CDR3LC and CDR3HC regions as tolerated (T), moderately tolerated (MT) or intolerant (NT). Alanine mutations at residues that TCE-9 causes significant weakening of binding relative to the non-mutated TCE construct are characterized as NT, and those residues are considered to be key residues for CD3ε binding. Alanine mutations at residues that show comparable binding parameters with TCE-9 are characterized as T, and are considered to be uncritical for CD3ε binding. Alanine mutations at residues that cause slight weakening of binding relative to TCE-9 are characterized as MT.
[0465] As can be seen from Table 33, alanine mutations at residues W233 and W238 of anti-CD3 CDR3 LC are not tolerated, indicating that these residues are important for binding to CD3. In addition, Tables 34-35 demonstrate that alanine mutations at N103, F104, Y111 and W112 of anti-CD3 CDR3 HC are not tolerated, indicating that these residues are also important for binding to CD3.
[0466] Table 33. CD3ε binding and SAR data for anti-CD3 CDR3 LC alanine scanning mutants
[0467]
[0468] Table 34. CD3ε binding and SAR data for anti-CD3 CDR3 HC alanine scanning mutants
[0469]
[0470] Table 35. CD3ε binding and SAR data for anti-CD3 CDR3 HC alanine scanning mutants
[0471]
[0472] Example 9: Tumor cell killing by TROP2 TCE
[0473] TCE was evaluated in a functional in vitro tumor cell killing assay using H292, HCT116 or HEK293 cell lines. Recombinant HEK293 cell lines were engineered to express human or cynomolgus monkey TROP2 on their surface. Tumor cell killing was measured using the xCelligence real-time cell analyzer from Agilent, which relies on sensor impedance measurements (cell index) that increase as tumor cells adhere, spread and amplify on the sensor surface. Similarly, as tumor cells are killed, impedance decreases. 10,000 tumor cells were added to each well and allowed to adhere overnight. The next day, TCE titrated in a culture medium supplemented with human serum was added to the wells together with 30,000 CD8+T cells. Cell index measurements were performed every 10 minutes for another 72 hours. The cell index was then multiplied by the number of hours (tumor cell growth kinetics) relative to the TCE concentration plot, where the concentration required to reduce tumor growth by 50% (EC 50 ). For TCE-9, TCE-11, TCE-12, and TCE-14 mediated killing of H292 tumor cells, the data graphs of tumor cell viability versus TCE concentration are shown in Fig.36 Shown in. Fig.37 Shown is a data graph of tumor cell viability versus TCE concentration for TCE-15, TCE-21, TCE-23, and TCE-27 mediated killing of H292 tumor cells. Fig.38 Figure 2 shows the data of H292 tumor cell viability of TCE-32, TCE-34, TCE-35 and TCE-36 versus TCE concentration. 50 Provided in Tables 36-38.
[0474] Table 36. TCE cytotoxicity EC 50 (H292 cells) - Mutated CDRH3
[0475]
[0476] Table 37. TCE cytotoxicity EC 50 (H292 cells) - Mutated CDRL3
[0477]
[0478] Table 38. TCE cytotoxicity EC 50 (H292 cells)
[0479]
[0480] The data of tumor cell killing by TCE-37, TCE-40, TCE-41 and TCE-42 are shown in Fig.39 (HCT116 cells), Fig.40 (H292 cells) and Fig.41 (Cynomolgus monkey TROP2HEK293 cells). The data of TCE-38 and TCE-40 killing H292 tumor cells are shown in Fig.42 The data of TCE-39 killing H292 tumor cells is shown in Fig.43 The data of TCE-37, TCE-38, TCE-39 and TCE-40 killing of cynomolgus monkey TROP2HEK293 cells are shown in Fig.44 The data of tumor cell killing by TCE-47 and TCE-43 are shown in Fig.45 (H292 cells) and Fig.46 (Cynomolgus monkey TROP2HEK293 cells). The data of tumor cell killing by TCE-45 and TCE-43 are shown in Fig.47 (H292 cells) and Fig.48 (Cynomolgus monkey TROP2HEK293 cells) are shown. The cytotoxic EC values of different TCEs 50 Provided in Tables 39-41.
[0481] Table 39. TCE cytotoxicity EC 50 (HCT116 cells)
[0482]
[0483] Table 40. TCE cytotoxicity EC 50 (H292 cells)
[0484]
[0485] Table 41. TCE cytotoxicity EC 50 (Cynomolgus monkey TROP2+HEK293 cells)
[0486]
[0487] Example 10: TROP2 TCE Non-human Primate (NHP) Study NHP toxicity study of TCE-37 and TCE-43
[0488] The pharmacokinetics and exploratory safety of TCE-37 (wt anti-CD3, anti-TROP2 F108A mutant) and TCE-43 (wt anti-CD3, anti-TROP2 D109A mutant) were evaluated in cynomolgus monkeys. In brief, TCE was administered by continuous IV (cIV) infusion to monkeys weighing approximately 3 kilograms (kg). Animals were observed for signs of adverse events. TCE-43 was administered at a dose of 0.15 micrograms / kilogram / day (μg / kg / day), 0.5μg / kg / day, 5μg / kg / day, and 15μg / kg / day. TCE-37 was administered at a dose of 0.5μg / kg / day, 1.5μg / kg / day, 5μg / kg / day, and 15μg / kg / day. After administration, blood was collected in K2EDTA tubes at specific time points and processed into plasma. The plasma was frozen until analysis. The concentration of TCE in plasma was measured by a Meso Scale Discovery (MSD)-based method relative to a reference standard diluted in control cynomolgus monkey plasma. Fig.49 (TCE-43) and Fig.50 (TCE-37) is shown. Overall, TCE-43 and TCE-37 both show an increase in exposure proportional to the dose. As shown in the figure, the maximum acceptable dose (MTD) of TCE-43 and TCE-37 is 0.15 μg / kg / day and 0.5 μg / kg / day, respectively. Mild to moderate gastrointestinal (GI) and skin manifestations were observed at these doses.
[0489] Cytokine induction by TCE-37 and TCE-43 in NHPs
[0490] Cytokine release after TCE-37 and TCE-43 are administered by cIV is assessed in cynomolgus monkeys. In brief, an infusion pump is implanted subcutaneously to a cynomolgus monkey weighing about 3 kg. After two weeks, the pump is filled with TCE dosing solution and administered via continuous infusion. After administration is started, blood is collected in a K2 EDTA tube and processed into plasma at a specific time point. Using the non-human primate cytometry Th1 / Th2 bead array kit from BDbiosciences, according to the manufacturer's instructions, the cytokines of plasma samples are analyzed. Interleukin 6 (IL-6) levels in plasma are calculated relative to the reference standard provided by the bead array kit. Figure 51-Figure 52 Continuous infusion of TCE-43 ( Fig.51 ) and TCE-37( Fig.52) in cynomolgus monkeys after cIV infusion. The IL-6 levels (in pg / mL) after 10 days of cIV infusion at different doses are provided in Table 42 (for TCE-43) and Table 43 (for TCE-37).
[0491] Table 42. NHP Continuous IV Infusion of TCE-43 for 10 Days
[0492] 0.15 μg / kg / day 0.5 μg / kg / day 5 μg / kg / day 15 μg / kg / day 3458pg / mL IL-6 298pg / mL IL-6 2006pg / mL IL-6 7098pg / mL IL-6
[0493] Table 43. NHP Continuous IV Infusion of TCE-37 for 10 Days
[0494] 0.5 μg / kg / day 1.5 μg / kg / g / day 5 μg / kg / day 15 μg / kg / day 356pg / mL IL-6 324pg / mL IL-6 3719pg / mL IL-6 8811pg / mL IL-6
[0495] Clinical chemistry of TCE-37 and TCE-43 in NHPs
[0496] Clinical chemistry after TCE-37 and TCE-43 were administered by cIV in cynomolgus monkeys was measured by standard group analysis. In brief, TCE was administered by cIV to cynomolgus monkeys weighing about 3 kg and signs of adverse events were observed every day. After administration, blood was collected in K2EDTA tubes and processed into plasma at specific time points. Clinical chemistry parameters were tested on freshly prepared plasma samples, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), bilirubin (TBIL), creatinine (CRE) and blood urea nitrogen (BUN) as signs of liver and kidney related toxicity. Figures 53-54 show the administration of TCE-43 ( Figure 53A-53F ) and TCE-37( Figure 54A-Figure 54F ) Graph of ALT, AST, ALP, TBIL, CRE, and BUN levels in cynomolgus monkeys after .
[0497] NHP toxicity study of TCE-39, TCE-40 and TCE-42
[0498] The pharmacokinetics and exploratory safety of TCE-39, TCE-40, and TCE-42 were evaluated as described above. Fig.55 (TCE-39), Fig.56 (TCE-42) and Fig.57 As shown in the figure, the maximum tolerated dose of TCE-39 is 30 μg / kg / day, TCE-42 is 1 μg / kg / day, and TCE-40 is 30 μg / kg / day.
[0499] Cytokine induction by TCE-39, TCE-40, and TCE-42 in NHPs
[0500] Cytokine release following cIV administration of TCE-39, TCE-40, and TCE-42 was assessed in cynomolgus monkeys as described above. Figure 58A-Figure 58D Shown is the release of IL-6, tumor necrosis factor alpha (TNFα), interferon gamma (IFNγ), and interleukin 2 (IL-2) in cynomolgus monkeys following continuous infusion of TCE-39. Figure 59A-Figure 59D Shown is the release of IL-6, TNFα, IFNγ, and IL-2 in cynomolgus monkeys following continuous infusion of TCE-42. Fig.60 The release of IL-6 in cynomolgus monkeys after continuous infusion of TCE-40 is shown. The IL-6 levels in pg / mL after 10 days of cIV infusion at different doses are provided in Table 44 (for TCE-39), Table 45 (for TCE-40), and Table 46 (for TCE-42).
[0501] Table 44. NHP Continuous IV Infusion of TCE-39 for 10 Days
[0502] 30 μg / kg / day 100 μg / kg / day 197pg / mL IL-6 100pg / mL IL-6
[0503] Table 45. NHP continuous IV infusion of TCE-40 for 10 days
[0504] 30 μg / kg / day 100 μg / kg / day 183pg / mL IL-6 213pg / mL IL-6
[0505] Table 46. NHP Continuous IV Infusion of TCE-42 for 10 Days
[0506] 1 μg / kg / day 3 μg / kg / day IL-6, below the limit of quantification 133pg / mL IL-6
[0507] Clinical Chemistry of TCE-39, TCE-40, and TCE-42
[0508] Clinical chemistry following cIV administration of TCE-39, TCE-40, and TCE-42 in cynomolgus monkeys was measured by standard panel analysis as described above. Figure 61A-Figure 61F )、TCE-42( Figure 62A-62F ) and TCE-40( Figure 63A-Figure 63F ) Graph of ALT, AST, ALP, TBIL, CRE, and BUN levels in cynomolgus monkeys after .
[0509] Although preferred embodiments of the present disclosure have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided only as examples. Without departing from the present disclosure, those skilled in the art will now expect many variations, changes and substitutions. It should be understood that various alternatives of the disclosed embodiments described herein may be adopted when practicing the present disclosure. The appended claims are intended to define the scope of the present disclosure, and therefore encompass methods and structures and their equivalents within the scope of these claims.
Claims
1. A recombinant antibody or an antigen-binding fragment thereof comprising a tumor-associated calcium signal transducer protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, wherein the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO: 1; wherein CDR2-L comprises the amino acid sequence of SEQ ID NO:2(SA); and Where CDR3-L contains X 1 X 2 HYX 3 X 4 X 5 X 6 X 7 The amino acid sequence of Where X 1 is Q, S, T, D, N, E, H, K, R or A; X 2 is Q, S, T, D, N, E, H, K, R or A; X 3 is I, G, P, V, L, M, S, T, or A; X 4 is T, G, S, M, H, N, Q or A; X 5 is P, G, V, L, I, M, S, T, or A; X 6 is L, G, P, V, I, M, S, T, or A; and X 7 is T, G, S, M, H, N, Q or A; wherein CDR1-H comprises the amino acid sequence of SEQ ID NO: 13; wherein CDR2-H comprises the amino acid sequence of SEQ ID NO: 14; and CDR3-H contains AX 8 X 9 GX 10 X 11 X 12 X 13 YW 14 X 15 X 16 X 17 The amino acid sequence of Where X 8 is R, S, T, Q, D, E, H, K, N, H, K, or A; X 9 is G, P, V, L, I, M, S, T, or A; X 10 is F, Y, W, V, L, I, G, or A; X 11 is G, P, V, L, I, M, S, T, or A; X 12 is S, G, T, M, N, Q, H or A; X 13 is S, G, T, M, N, Q, H or A; X 14 is Y, F, W, V, L, I, G or A; X 15 is F, Y, W, V, L, I, G, or A; X 16 is D, Q, N, E, S, T, H, K, R, or A; and X 17 is V, G, P, L, I, M, S, T, or A; Wherein when CDR3-H comprises the amino acid sequence of SEQ ID NO:15, CDR3-L does not comprise the amino acid sequence of SEQ ID NO:
3.
2. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein X 1 is Q, N, D, E or A; X 2 is Q, N, D, E or A; X 3 is I, V, L or A; X 4 is T, S or A; X 5 is P, G or A; X 6 is L, V, I or A; X 7 is T, S or A; X 8 is R, K or A; X 9 is G, S, T or A; X 10 is F, Y or A; X 11 is G, S, T or A; X 12 is S, G, T or A; X 13 is S, G, T or A; X 14 is Y, W, F or A; X 15 is F, Y, W or A; X 16 is D, E, Q, N, or A; and X 17 It is V, L, I or A.
3. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein X 1 is Q; and X 6 It's L.
4. The recombinant antibody or antigen-binding fragment thereof according to claim 3, wherein X 8 It is R; X 10 It is F; X 11 It is G; X 14 It is Y; X 15 is F; and X 16 It is D.
5. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein X 1 is Q, S, T, D, N, E or A; X 2 is Q, S, T, D, N, E or A; X 3 is I, G, P, V, L, M, or A; X 4 is T, G, S, M, H, N, Q or A; X 5 is P, G, V, L, I, M or A; X 6 is L, G, P, V, I, M, or A; X 7 is T, G, S, M, H, N, Q or A; X 8 is R, H, K or A; X 9 is G, P, V, L, I, M, S, T, or A; X 10 is F, Y, W, V, L, I or A; X 11 is G, P, V, L, I, M, S, T, or A; X 12 is S, G, T, M, N, Q or A; X 13 is S, G, T, M, N, Q or A; X 14 is Y, F, W, V, L, I or A; X 15 is F, Y, W, V, L, I or A; X 16 is D, Q, N, E, S, T, or A; and X 17 It is V, G, P, L, I, M or A.
6. The recombinant antibody or antigen-binding fragment thereof according to claim 5, wherein X 1 is Q, N or A; X 2 is Q, N or A; X 3 is I, V, L or A; X 4 is T, S or A; X 5 is P, G or A; X 6 is L, V, I or A; X 7 is T, S or A; X 8 is R, K or A; X 9 is G, V, S, T or A; X 10 is F, Y or A; X 11 is G, V, S, T or A; X 12 is S, G, T or A; X 13 is S, G, T or A; X 14 is Y, W or A; X 15 is F, Y or A; X 16 is D, E or A; and X 17 It is V, G, L, I or A.
7. The recombinant antibody or antigen-binding fragment thereof according to claim 5, wherein X 1 is Q; and X 6 It's L.
8. The recombinant antibody or antigen-binding fragment thereof according to claim 7, wherein X 8 It is R; X 10 It is F; X 11 It is G; X 14 It is Y; X 15 is F; and X 16 It is D.
9. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein CDR3-L comprises amino acids selected from SEQ ID NOs: 3-5 and 8-12.
10. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:4 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:5 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:8 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:10 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:11 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:12 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:
15.
11. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:5 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:8 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:10 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 15; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:12 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:
15.
12. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein CDR3-H comprises amino acids selected from SEQ ID NOs: 16-17, 19-22 and 25-28.
13. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14; CDR3-H: SEQ ID NO:16; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:17; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:19; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:20; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:22; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:25; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:26; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 27; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:
28.
14. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:17; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO: 13, CDR2-H: SEQ ID NO: 14, CDR3-H: SEQ ID NO: 22; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:
28.
15. A recombinant antibody or antigen-binding fragment thereof comprising a tumor-associated calcium signal transducer protein 2 (TROP2) binding domain, wherein the TROP2 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, wherein the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the following: CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:4 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:5 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:6 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:7 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:8 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:9 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:10 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:11 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:12 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:15; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:16; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:17; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:18; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:19; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:20; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA); CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:21; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA); CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14; CDR3-H: SEQ ID NO:22; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:23; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:24; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:25; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:26; CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:27; and CDR1-L: SEQ ID NO:1, CDR2-L: SEQ ID NO:2(SA), CDR3-L: SEQ ID NO:3 and CDR1-H: SEQ ID NO:13, CDR2-H: SEQ ID NO:14, CDR3-H: SEQ ID NO:
28.
16. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the TROP2 binding domain comprises Fab, Fab', (Fab') 2 or single-chain variable fragment (scFv).
17. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the TROP2 binding domain is Fab.
18. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises a variable domain of an immunoglobulin kappa (IgK) or immunoglobulin lambda (IgL) light chain.
19. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin heavy chain comprises the variable domain of an IgG1, IgG2, IgG3 or IgG4 heavy chain.
20. The recombinant antibody or antigen-binding fragment thereof of claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO: 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71 or 73.
21. The recombinant antibody or antigen-binding fragment thereof of claim 1, wherein the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO:32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72 or 74.
22. The recombinant antibody or antigen-binding fragment thereof of claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:31, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
32.
23. The recombinant antibody or antigen-binding fragment thereof of claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:33, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
34.
24. The recombinant antibody or antigen-binding fragment thereof of claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:35, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
36.
25. The recombinant antibody or antigen-binding fragment thereof of claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:37, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
38.
26. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:39, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
40.
27. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:41, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
42.
28. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:43, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
44.
29. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:45, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
46.
30. The recombinant antibody or antigen-binding fragment thereof of claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:47, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
48.
31. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:49, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
50.
32. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:51, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
52.
33. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:53, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
54.
34. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:55, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
56.
35. The recombinant antibody or antigen-binding fragment thereof of claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:57, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
58.
36. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:59, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
60.
37. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:61, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
62.
38. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:63, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
64.
39. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:65, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
66.
40. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:67, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
68.
41. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:69, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
70.
42. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:71, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
72.
43. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin light chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:73, and the immunoglobulin heavy chain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
74.
44. The recombinant antibody or antigen-binding fragment thereof of claim 1, wherein the TROP2 binding domain has weaker binding to TROP2 than a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO:29 and an immunoglobulin heavy chain according to SEQ ID NO:30 as measured by ELISA under substantially similar assay conditions.
45. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the TROP2 binding domain has an increased EC for TROP2 compared to a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO: 29 and an immunoglobulin heavy chain according to SEQ ID NO: 30 as measured by ELISA under substantially similar assay conditions. 50 .
46. The recombinant antibody or antigen-binding fragment thereof of claim 1, wherein the TROP2 binding domain has a faster dissociation rate (greater k) for TROP2 binding than a TROP2 binding domain comprising an immunoglobulin light chain according to SEQ ID NO: 29 and an immunoglobulin heavy chain according to SEQ ID NO: 30 as measured under substantially similar kinetic assay conditions. diss ).
47. The recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein the recombinant antibody or antigen-binding fragment further comprises a CD3 binding domain.
48. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, wherein the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO:75; wherein CDR2-L comprises the amino acid sequence of SEQ ID NO:76; wherein CDR3-L comprises the amino acid sequence of SEQ ID NO:77; wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:78; wherein CDR2-H comprises the amino acid sequence of SEQ ID NO:79; and Wherein CDR3-H comprises the amino acid sequence of SEQ ID NO:
80.
49. The recombinant antibody or antigen-binding fragment thereof according to claim 47, wherein the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, wherein the immunoglobulin light chain comprises complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprises CDRs: CDR1-H, CDR2-H and CDR3-H, wherein CDR1-L comprises the amino acid sequence of SEQ ID NO:75; wherein CDR2-L comprises the amino acid sequence of SEQ ID NO:76; CDR3-L contains Z 1 -Z 2 -WZ 3 -Z 4 -Z 5 -Z 6 -WZ 7 -Z 8 The amino acid sequence of Where Z 1 is V, G, P, L, I, M, S, T, or A; Z 2 is L, G, P, V, I, M, S, T, or A; Z 3 is Y, F, W, V, L, I, G or A; Z 4 is S, G, T, M, N, Q, H or A; Z 5 is N, Q, S, T, D, E, H, K, R or A; Z 6 is R, S, T, Q, D, E, H, K, N or A; Z 7 is V, G, P, L, I, M, S, T, or A; and Z 8 is F, Y, W, V, L, I, G, or A; wherein CDR1-H comprises the amino acid sequence of SEQ ID NO:78; wherein CDR2-H comprises the amino acid sequence of SEQ ID NO:79; CDR3-H contains Z 9 -Z 10 -Z 11 -Z 12 -NZ 13 -Z 14 -Z 15 -Z 16 -Z 17 -Z 18 -Z 19 -YZ 20 -AZ 21 an amino acid sequence of Where Z 9 is V, G, P, L, I, M, S, T, or A; Z 10 is R, S, T, Q, D, E, H, K, N or A; Z 11 is H, R, K, G, T, S, N, Q or A; Z 12 is G, P, V, L, I, M, S, T, or A; Z 13 is F, Y, W, V, L, I, G, or A; Z 14 is G, P, V, L, I, M, S, T, or A; Z 15 is N, Q, S, T, D, E, H, K, R or A; Z 16 is S, G, T, M, N, Q, H or A; Z 17 is Y, F, W, V, L, I, G or A; Z 18 is I, G, P, V, L, M, S, T, or A; Z 19 is S, G, T, M, N, Q, H or A; Z 20 is W, F, Y, V, L, I, G or A; and Z 21 It is Y, F, W, V, L, I, G or A.
50. The recombinant antibody or antigen-binding fragment thereof according to claim 49, in: Z 1 is V, G, L, I or A; Z 2 is L, V, I or A; Z 3 is Y, W, F or A; Z 4 is S, G, T or A; Z 5 is N, Q, D, E or A; Z 6 is R, K or A; Z 7 is V, G, L, I or A; Z 8 is F, Y, W or A; Z 9 is V, G, L, I or A; Z 10 is R, K or A; Z 12 is G, S, T or A; Z 13 is F, Y, W or A; Z 14 is G, S, T or A; Z 15 is N, Q, D, E or A; Z 16 is S, G, T or A; Z 17 is Y, W, F or A; Z 18 is I, V, L or A; Z 19 is S, G, T or A; Z 20 is W, Y, F or A; and Z 21 It is Y, W, F or A.
51. The recombinant antibody or antigen-binding fragment thereof according to claim 49, in: Z 8 It's F.
52. The recombinant antibody or antigen-binding fragment thereof according to claim 49, in: Z 10 It is R; Z 11 It is H; Z 13 It is F; Z 18 It's I; Z 19 is S; and Z 20 It's W.
53. The recombinant antibody or antigen-binding fragment thereof according to claim 49, wherein CDR3-L comprises an amino acid sequence selected from SEQ ID NO: 77, 105-106, 108-111 and 113-114.
54. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:105 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:106 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:108 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:114 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:
80.
55. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:105 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:106 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:108 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 80; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:
80.
56. The recombinant antibody or antigen-binding fragment thereof according to claim 49, wherein CDR3-H comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 80, 116-119, 121-127 and 129-130.
57. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:116; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:117; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:118; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:121; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:125; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:126; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:127; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:129; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:
130.
58. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the group consisting of: CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:116; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 125; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:
130.
59. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the CD3 binding domain comprises an immunoglobulin light chain and an immunoglobulin heavy chain, the immunoglobulin light chain comprising complementarity determining regions (CDRs) CDR1-L, CDR2-L and CDR3-L, and the immunoglobulin heavy chain comprising CDRs: CDR1-H, CDR2-H and CDR3-H, wherein the immunoglobulin light chain and the immunoglobulin heavy chain comprise a set of CDR sequences selected from the following: CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:105 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:106 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:107 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:108 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:109 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:110 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:111 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:112 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:113 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:114 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:80; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:116; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:117; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:118; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:119; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:120; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:121; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:122; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:123; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:124; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:125; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:126; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:127; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:128; CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO: 78, CDR2-H: SEQ ID NO: 79, CDR3-H: SEQ ID NO: 129; and CDR1-L: SEQ ID NO:75, CDR2-L: SEQ ID NO:76, CDR3-L: SEQ ID NO:77 and CDR1-H: SEQ ID NO:78, CDR2-H: SEQ ID NO:79, CDR3-H: SEQ ID NO:
130.
60. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the immunoglobulin light chain of the CD3 binding domain comprises a variable domain of an immunoglobulin kappa (IgK) or immunoglobulin lambda (IgL) light chain.
61. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the immunoglobulin heavy chain of the CD3 binding domain comprises a variable domain of an IgG1, IgG2, IgG3 or IgG4 heavy chain.
62. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the immunoglobulin light chain of the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
81.
63. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the immunoglobulin heavy chain of the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
82.
64. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the immunoglobulin light chain of the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:81, and the immunoglobulin heavy chain of the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
82.
65. The recombinant antibody or antigen-binding fragment thereof according to claim 47, wherein the CD3 binding domain comprises Fab, Fab', (Fab') 2 or single-chain variable fragment (scFv).
66. The recombinant antibody or antigen-binding fragment thereof of claim 65, wherein the CD3 binding domain is a scFv.
67. The recombinant antibody or antigen-binding fragment thereof of claim 48, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
99.
68. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
131.
69. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
132.
70. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
133.
71. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
134.
72. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
135.
73. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
136.
74. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
137.
75. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
138.
76. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
139.
77. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
140.
78. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
141.
79. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
142.
80. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
143.
81. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
144.
82. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
145.
83. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
146.
84. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
147.
85. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
148.
86. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
149.
87. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
150.
88. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
151.
89. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
152.
90. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
153.
91. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
154.
92. The recombinant antibody or antigen-binding fragment thereof of claim 49, wherein the CD3 binding domain comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
155.
93. The recombinant antibody or antigen-binding fragment thereof according to claim 48, wherein the N-terminus of the immunoglobulin heavy chain of the TROP2 binding domain binds to the C-terminus of the immunoglobulin light chain of the CD3 binding domain.
94. The recombinant antibody or antigen-binding fragment thereof according to claim 48, wherein the C-terminus of the immunoglobulin heavy chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin light chain of the CD3 binding domain.
95. The recombinant antibody or antigen-binding fragment thereof according to claim 48, wherein the N-terminus of the immunoglobulin heavy chain of the TROP2 binding domain is bound to the C-terminus of the immunoglobulin heavy chain of the CD3 binding domain.
96. The recombinant antibody or antigen-binding fragment thereof according to claim 48, wherein the C-terminus of the immunoglobulin heavy chain of the TROP2 binding domain is bound to the N-terminus of the immunoglobulin heavy chain of the CD3 binding domain.
97. The recombinant antibody or antigen-binding fragment thereof of claim 48, wherein the N-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the C-terminus of the immunoglobulin light chain of the CD3 binding domain.
98. The recombinant antibody or antigen-binding fragment thereof according to claim 48, wherein the C-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the N-terminus of the immunoglobulin light chain of the CD3 binding domain.
99. The recombinant antibody or antigen-binding fragment thereof according to claim 48, wherein the N-terminus of the immunoglobulin light chain of the TROP2 binding domain binds to the C-terminus of the immunoglobulin heavy chain of the CD3 binding domain.
100. The recombinant antibody or antigen-binding fragment thereof according to claim 48, wherein the C-terminus of the immunoglobulin light chain of the TROP2 binding domain is bound to the N-terminus of the immunoglobulin heavy chain of the CD3 binding domain.
101. The recombinant antibody or antigen-binding fragment thereof according to claim 48, wherein the CD3 binding domain is a scFv and the TROP2 binding domain is a Fab or Fab'.
102. The recombinant antibody or antigen-binding fragment thereof according to claim 101, wherein the scFv is bound to the immunoglobulin heavy chain of the Fab or Fab'.
103. The recombinant antibody or antigen-binding fragment thereof according to claim 101, wherein the scFv is bound to the immunoglobulin light chain of the Fab or Fab'.
104. The recombinant antibody or antigen-binding fragment thereof according to claim 101, wherein the immunoglobulin light chain of the scFv is bound to the immunoglobulin heavy chain of the Fab or Fab'.
105. The recombinant antibody or antigen-binding fragment thereof according to claim 101, wherein the immunoglobulin light chain of the scFv is bound to the immunoglobulin light chain of the Fab or Fab'.
106. The recombinant antibody or antigen-binding fragment thereof according to claim 101, wherein the immunoglobulin heavy chain of the scFv is bound to the immunoglobulin heavy chain of the Fab or Fab'.
107. The recombinant antibody or antigen-binding fragment thereof according to claim 101, wherein the immunoglobulin heavy chain of the scFv is bound to the immunoglobulin light chain of the Fab or Fab'.
108. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:87 and SEQ ID NO:
88.
109. A recombinant antibody or antigen-binding fragment thereof according to claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:89 and SEQ ID NO:
90.
110. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:91 and SEQ ID NO:
92.
111. A recombinant antibody or antigen-binding fragment thereof according to claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:93 and SEQ ID NO:
94.
112. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:95 and SEQ ID NO:
96.
113. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:97 and SEQ ID NO:
98.
114. A recombinant antibody or antigen-binding fragment thereof according to claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 158 and SEQ ID NO:
188.
115. The recombinant antibody or antigen-binding fragment thereof of claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 158 and SEQ ID NO:
189.
116. A recombinant antibody or antigen-binding fragment thereof according to claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 158 and SEQ ID NO:
190.
117. A recombinant antibody or antigen-binding fragment thereof according to claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 158 and SEQ ID NO:
194.
118. A recombinant antibody or antigen-binding fragment thereof according to claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 158 and SEQ ID NO:
195.
119. A recombinant antibody or antigen-binding fragment thereof according to claim 47, wherein the recombinant antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 158 and SEQ ID NO:
196.
120. A recombinant antibody or antigen-binding fragment thereof according to claim 47, wherein the recombinant antibody or antigen-binding fragment thereof has weaker cytotoxic activity than a recombinant antibody or antigen-binding fragment thereof comprising an immunoglobulin light chain according to SEQ ID NO: 83 or 85 and an immunoglobulin heavy chain according to SEQ ID NO: 84 or 86, as measured in an in vitro tumor cell killing assay under substantially similar assay conditions.
121. A pharmaceutical composition comprising: (i) the recombinant antibody or antigen-binding fragment thereof according to claim 1; and (ii) a pharmaceutically acceptable excipient.
122. An isolated recombinant nucleic acid molecule encoding a polypeptide of the recombinant antibody or antigen-binding fragment thereof of claim 1.
123. A method of treating cancer in a subject in need thereof, comprising administering to the subject the recombinant antibody or antigen-binding fragment thereof of claim 1.
124. The method of claim 123, wherein the cancer comprises breast cancer, lung cancer, urothelial cancer, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, head and neck cancer, or glioma.
125. The method of claim 124, wherein the breast cancer comprises triple negative breast cancer.
126. The method of claim 124, wherein the lung cancer comprises non-small cell lung cancer.
Citation Information
Patent Citations
Chemical vapor deposition wafer boat
US4694778A
